| 1 |
Jiang S, Cai M, Zhang Z, Qian C, Wang J, Li Z, Guo Q, Zhou H, Xin H, Cai W, Wang H, Guo S, Huang Y, Xie Q. The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance. Hum Vaccin Immunother 2023;19:2161254. [PMID: 36683193 DOI: 10.1080/21645515.2022.2161254] [Reference Citation Analysis]
|
| 2 |
Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol 2023;11:480-9. [PMID: 36643046 DOI: 10.14218/JCTH.2022.00293] [Reference Citation Analysis]
|
| 3 |
Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology 2023;77:1382-403. [PMID: 35993341 DOI: 10.1002/hep.32743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Huang P, Zhou C, Wu F, Xiao Y, Qian X, Wang Y, Yang C, Zeng M. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. Eur Radiol 2023;33:2735-45. [PMID: 36472696 DOI: 10.1007/s00330-022-09282-5] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Criss C, Nagar AM, Makary MS. Hepatocellular carcinoma: State of the art diagnostic imaging. World J Radiol 2023; 15(3): 56-68 [DOI: 10.4329/wjr.v15.i3.56] [Reference Citation Analysis]
|
| 6 |
Gong W, Wu J, Wei H, Jiang Z, Wan M, Wu C, Xue W, Ma R, Zhou X, Zhou H. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients. Radiol Med 2023. [PMID: 36943653 DOI: 10.1007/s11547-023-01614-9] [Reference Citation Analysis]
|
| 7 |
Yang J, Yang Z, Zeng X, Yu S, Gao L, Jiang Y, Sun F. Comparative effectiveness of different hepatocellular carcinoma screening intervals or modalities: a systematic review and meta-analysis. Chin Med J (Engl) 2023. [PMID: 36921104 DOI: 10.1097/CM9.0000000000002341] [Reference Citation Analysis]
|
| 8 |
He M, Liu S, Lai Z, Du Z, Li Q, Xu L, Kan A, Shen J, Shi M. Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Curr Opin Pharmacol 2023;70:102362. [PMID: 36931163 DOI: 10.1016/j.coph.2023.102362] [Reference Citation Analysis]
|
| 9 |
Huang J, Gao L, Li J, Yang R, Jiang Z, Liao M, Luo Y, Lu Q. Head-to-head comparison of Sonazoid and SonoVue in the diagnosis of hepatocellular carcinoma for patients at high risk. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1140277] [Reference Citation Analysis]
|
| 10 |
Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther 2023. [PMID: 36914943 DOI: 10.1111/apt.17438] [Reference Citation Analysis]
|
| 11 |
Pan J, Song M, Yang L, Zhao Y, Zhu Y, Wang M, Chen F. The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Eur Radiol 2023. [PMID: 36894754 DOI: 10.1007/s00330-023-09487-2] [Reference Citation Analysis]
|
| 12 |
Lin CL, Chien RN, Chen LW, Chu YD, Yeh CT. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Cancer Biomark 2023. [PMID: 36938726 DOI: 10.3233/CBM-220042] [Reference Citation Analysis]
|
| 13 |
Hsueh K, Lee C, Huang P, Liang C, Yang S. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. Current Oncology 2023;30:3206-3216. [DOI: 10.3390/curroncol30030243] [Reference Citation Analysis]
|
| 14 |
Qiu L, Xu S, Qiu Y, Liu Y, Zhang J. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response. J Viral Hepat 2023. [PMID: 36890735 DOI: 10.1111/jvh.13829] [Reference Citation Analysis]
|
| 15 |
Wong JK, Lim HJ, Tam VC, Burak KW, Dawson LA, Chaudhury P, Abraham RJ, Meyers BM, Sapisochin G, Valenti D, Samimi S, Ramjeesingh R, Mujoomdar A, Martins I, Dixon E, Segedi M, Liu DM. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev 2023;115:102526. [PMID: 36924644 DOI: 10.1016/j.ctrv.2023.102526] [Reference Citation Analysis]
|
| 16 |
Grazzini G, Chiti G, Zantonelli G, Matteuzzi B, Pradella S, Miele V. Imaging in Hepatocellular Carcinoma: what's new? Seminars in Ultrasound, CT and MRI 2023. [DOI: 10.1053/j.sult.2023.03.002] [Reference Citation Analysis]
|
| 17 |
Lee HN, Hyun D. Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review. Korean J Radiol 2023;24:204-23. [PMID: 36788765 DOI: 10.3348/kjr.2022.0395] [Reference Citation Analysis]
|
| 18 |
Yoshihara T, Hasegawa T, Sato Y, Yamaura H, Murata S, Chatani S, Tsukii R, Nagasawa K, Tsushima Y, Inaba Y. Clinical Outcomes of Radiofrequency Ablation Combined with Transarterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Non-hepatocellular Carcinoma Malignant Liver Tumors. Interv Radiol (Higashimatsuyama) 2023;8:7-13. [PMID: 36936255 DOI: 10.22575/interventionalradiology.2022-0017] [Reference Citation Analysis]
|
| 19 |
Li C, Lu X, Gao F, Lee E, Chan CW. Development of a nurse-led decision counselling program for improving hepatocellular carcinoma screening: A typology-guided feasibility study. Asia-Pacific Journal of Oncology Nursing 2023. [DOI: 10.1016/j.apjon.2023.100215] [Reference Citation Analysis]
|
| 20 |
Hsieh PM, Hsiao P, Chen YS, Yeh JH, Hung CM, Lin HY, Ma CH, Tang T, Huang YW, Cheng PN, Hsieh KC, Hu KC, Bair MJ, Lin CW. Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis. Kaohsiung J Med Sci 2023;39:302-10. [PMID: 36625289 DOI: 10.1002/kjm2.12640] [Reference Citation Analysis]
|
| 21 |
Sultan LR, Karmacharya MB, Al-Hasani M, Cary TW, Sehgal CM. Hydralazine-augmented contrast ultrasound imaging improves the detection of hepatocellular carcinoma. Med Phys 2023;50:1728-35. [PMID: 36680519 DOI: 10.1002/mp.16232] [Reference Citation Analysis]
|
| 22 |
Wu Y, Liu H, Chen Y, Zeng J, Huang Q, Zhang J, Zeng Y, Liu J. Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection. Cancer Med 2023;12:5233-44. [PMID: 36354141 DOI: 10.1002/cam4.5328] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Qian XJ, Wen ZM, Huang XM, Feng HJ, Lin SS, Liu YN, Li SC, Zhang Y, Peng WG, Yang JR, Zheng ZY, Zhang L, Zhang DW, Lu FM, Liu LJ, Pan WD. Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin. World J Gastroenterol 2023; 29(8): 1359-1373 [DOI: 10.3748/wjg.v29.i8.1359] [Reference Citation Analysis]
|
| 24 |
Breder VV, Alikhanov RB, Bagnenko SS, Bessonova EN, Isakov VA, Kudashkin NE, Medvedeva BM, Mishchenko AV, Novruzbekov MS, Rudakov VS. Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2023;32:16-23. [DOI: 10.22416/1382-4376-2022-32-5-16-23] [Reference Citation Analysis]
|
| 25 |
Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Xie H. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol 2023;15:129-50. [PMID: 36926237 DOI: 10.4254/wjh.v15.i2.129] [Reference Citation Analysis]
|
| 26 |
Singal AG, Sanduzzi-zamparelli M, Nahon P, Ronot M, Hoshida Y, Rich N, Reig M, Vilgrain V, Marrero J, Llovet JM, Parikh ND, Villanueva A. International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance. Journal of Hepatology 2023. [DOI: 10.1016/j.jhep.2023.02.022] [Reference Citation Analysis]
|
| 27 |
Li T, Guo J, Liu Y, Du Z, Guo Z, Fan Y, Cheng L, Zhang Y, Gao X, Zhao Y, He X, Wu W, Gao N, Wu Y, Li J, Zhang Y, Kang W, Cai Z, Wang W, Li X, Zan Y, Nguyen MH, Ji F. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. Cancer Immunol Immunother 2023. [PMID: 36840762 DOI: 10.1007/s00262-023-03404-8] [Reference Citation Analysis]
|
| 28 |
Lee C, Shen C, Yen C, Yen T, Hsieh S. Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy. JPM 2023;13:397. [DOI: 10.3390/jpm13030397] [Reference Citation Analysis]
|
| 29 |
Joseph Yeoh YK, Dore GJ, Lockart I, Danta M, Flynn C, Blackmore C, Levy MT, George J, Alavi M, Hajarizadeh B. Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia.. [DOI: 10.1101/2023.02.20.23286164] [Reference Citation Analysis]
|
| 30 |
Meng Y, Jiang B, Yan K, Wang S, Zhang Z, Chen L, Wu W, Yang W. Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder. Int J Hyperthermia 2023;40:2182748. [PMID: 36822596 DOI: 10.1080/02656736.2023.2182748] [Reference Citation Analysis]
|
| 31 |
Sun Z, Shi Z, Xin Y, Zhao S, Jiang H, Li J, Li J, Jiang H. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. Acad Radiol 2023:S1076-6332(22)00687-0. [PMID: 36803649 DOI: 10.1016/j.acra.2022.12.031] [Reference Citation Analysis]
|
| 32 |
Cespiati A, Cinque F, Meroni M, Lombardi R, Dongiovanni P, Fracanzani AL. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. Biomedicines 2023;11. [PMID: 36831120 DOI: 10.3390/biomedicines11020586] [Reference Citation Analysis]
|
| 33 |
Ni Z, Wu B, Liu Z, Wang Q, Han X, Cheng W, Guo C. Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation. Br J Radiol 2023;:20220887. [PMID: 36715151 DOI: 10.1259/bjr.20220887] [Reference Citation Analysis]
|
| 34 |
El-Khobar KE, Sukowati CHC. Updates on Organoid Model for the Study of Liver Cancer. Technol Cancer Res Treat 2023;22:15330338231154090. [PMID: 36788421 DOI: 10.1177/15330338231154090] [Reference Citation Analysis]
|
| 35 |
Chen G, Zhang C, Li D, Luo D, Liao H, Huang P, Wang N, Feng Y. HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. Biomolecules 2023;13. [PMID: 36830729 DOI: 10.3390/biom13020360] [Reference Citation Analysis]
|
| 36 |
Yao CC, Wang JH, Chen CH, Hung CH, Yen YH, Kee KM, Hu TH, Tsai MC, Kuo YH, Lu SN. Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Diagnostics (Basel) 2023;13. [PMID: 36832184 DOI: 10.3390/diagnostics13040696] [Reference Citation Analysis]
|
| 37 |
Candita G, Rossi S, Cwiklinska K, Fanni SC, Cioni D, Lencioni R, Neri E. Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review. Diagnostics (Basel) 2023;13. [PMID: 36832113 DOI: 10.3390/diagnostics13040625] [Reference Citation Analysis]
|
| 38 |
Huang P, Ni X, Zhou C, Shi Z, Wu F, Xiao Y, Yang C, Zeng M. Subcentimeter Nodules with Diagnostic Hallmarks of Hepatocellular Carcinoma: Comparison of Pathological Features and Survival Outcomes with Nodules Measuring 1-2 cm. J Hepatocell Carcinoma 2023;10:169-80. [PMID: 36789251 DOI: 10.2147/JHC.S401027] [Reference Citation Analysis]
|
| 39 |
Yu J, Li Y, Shu C, Yang H, Huang Z, Tao R, Chen Y, Chen X, Xiao W. Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis.. [DOI: 10.21203/rs.3.rs-2554070/v1] [Reference Citation Analysis]
|
| 40 |
Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK, Ngeow JYY. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology 2023:S0016-5085(23)00105-1. [PMID: 36738977 DOI: 10.1053/j.gastro.2023.01.033] [Reference Citation Analysis]
|
| 41 |
Kim JH, Yoon JH, Bae JS, Park S, Han S, Lee JM. Multiarterial Phase Acquisition in Gadoxetic Acid-Enhanced Liver MRI for the Detection of Hypervascular Hepatocellular Carcinoma in High-Risk Patients: Comparison of Compressed Sensing Versus View Sharing Techniques. Invest Radiol 2023;58:139-47. [PMID: 35976759 DOI: 10.1097/RLI.0000000000000910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 42 |
Sun H, Shen Y, Huang C, Zhu X, Tan C, Tang Z, Fan J, Zhou J. The development and prospects of liver surgery. Clinical Surgical Oncology 2023. [DOI: 10.1016/j.cson.2023.100009] [Reference Citation Analysis]
|
| 43 |
Seif El Dahan K, Daher D, Singal AG. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S207-19. [PMID: 36103899 DOI: 10.3350/cmh.2022.0247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Cheng HY, Ho CM, Hsiao CY, Ho MC, Wu YM, Lee PH, Hu RH. Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. HPB (Oxford) 2023;25:218-28. [PMID: 36376221 DOI: 10.1016/j.hpb.2022.10.010] [Reference Citation Analysis]
|
| 45 |
Cholankeril G, El-Serag HB. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2023;43:89-99. [PMID: 36216350 DOI: 10.1055/a-1957-8540] [Reference Citation Analysis]
|
| 46 |
Lin Y, Lin X, Chen J, Lin Z. Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy.. [DOI: 10.21203/rs.3.rs-2254145/v1] [Reference Citation Analysis]
|
| 47 |
Granata V, Fusco R, De Muzio F, Cutolo C, Grassi F, Brunese MC, Simonetti I, Catalano O, Gabelloni M, Pradella S, Danti G, Flammia F, Borgheresi A, Agostini A, Bruno F, Palumbo P, Ottaiano A, Izzo F, Giovagnoni A, Barile A, Gandolfo N, Miele V. Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence. Biology (Basel) 2023;12. [PMID: 36829492 DOI: 10.3390/biology12020213] [Reference Citation Analysis]
|
| 48 |
Campani C, Zucman-Rossi J, Nault JC. Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA. Cancers (Basel) 2023;15. [PMID: 36765775 DOI: 10.3390/cancers15030817] [Reference Citation Analysis]
|
| 49 |
Lominadze Z, Hill K, Shaik MR, Canakis JP, Bourmaf M, Adams-Mardi C, Abutaleb A, Mishra L, Shetty K. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. Int J Mol Sci 2023;24. [PMID: 36768686 DOI: 10.3390/ijms24032358] [Reference Citation Analysis]
|
| 50 |
Liao JI, Ho SY, Liu PH, Hsu CY, Huang YH, Su CW, Hou MC, Huo TI. Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade. Cancers (Basel) 2023;15. [PMID: 36765711 DOI: 10.3390/cancers15030753] [Reference Citation Analysis]
|
| 51 |
Cassinotto C, Nogue E, Durand Q, Panaro F, Assenat E, Dohan A, Malafaye N, Guiu B, Molinari N. Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. Diagn Interv Imaging 2023:S2211-5684(23)00002-5. [PMID: 36682959 DOI: 10.1016/j.diii.2023.01.002] [Reference Citation Analysis]
|
| 52 |
Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H, Yang Y, Wang J, Su Q, Wang J, Chen K, Yu Z, Wang Y, Chen G. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765583 DOI: 10.3390/cancers15030625] [Reference Citation Analysis]
|
| 53 |
Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1] [Reference Citation Analysis]
|
| 54 |
Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
|
| 55 |
Lin CL, Liang KH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YH, Yeh CT. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36675198 DOI: 10.3390/ijms24021681] [Reference Citation Analysis]
|
| 56 |
Milana F, Polidoro MA, Famularo S, Lleo A, Boldorini R, Donadon M, Torzilli G. Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. Cancers (Basel) 2023;15. [PMID: 36672457 DOI: 10.3390/cancers15020508] [Reference Citation Analysis]
|
| 57 |
Abasseri M, Hoque S, Slavica Kochovska BA, Caldwell K, Sheahan L, Zekry A. Barriers to palliative care in hepatocellular carcinoma: A review of the literature. J Gastroenterol Hepatol 2023. [PMID: 36634200 DOI: 10.1111/jgh.16107] [Reference Citation Analysis]
|
| 58 |
You K, Guo T, Sun D, Song H, Liu Z. Transradial versus transfemoral approach for TACE: a retrospective study. BMC Gastroenterol 2023;23:11. [PMID: 36631744 DOI: 10.1186/s12876-023-02646-1] [Reference Citation Analysis]
|
| 59 |
Shi Q, Zhou X, Zhang Z, Zhang W, Ma J, Yang M, Yu J, Luo J, Liu L, Yan Z. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Front Immunol 2022;13:1097625. [PMID: 36703965 DOI: 10.3389/fimmu.2022.1097625] [Reference Citation Analysis]
|
| 60 |
Sirichindakul P, Sanguanlosit S, Taesombat W, Sutherasan M, Vorasittha A, Nonthasoot B. Cirrhotic and non-cirrhotic huge hepatocellular carcinoma (≥ 10 cm): a comparative study of surgical management and follow-up treatment in a single institution. Langenbecks Arch Surg 2023;408:18. [PMID: 36627380 DOI: 10.1007/s00423-023-02762-2] [Reference Citation Analysis]
|
| 61 |
Caviglia GP, Abate ML, Troshina G, Carucci P, Rolle E, Risso A, Burlone ME, Albè A, Crevola M, Musso EC, Rosso C, Armandi A, Olivero A, Minisini R, Saracco GM, Bugianesi E, Pirisi M, Ciancio A, Gaia S. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development. Biology (Basel) 2023;12. [PMID: 36671786 DOI: 10.3390/biology12010094] [Reference Citation Analysis]
|
| 62 |
Nagahara T, Sugihara T, Kihara T, Ikeda S, Hoshino Y, Matsuki Y, Sakaguchi T, Kurumi H, Onoyama T, Takata T, Matono T, Yamaguchi N, Isomoto H. The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages. Cancers (Basel) 2023;15. [PMID: 36672339 DOI: 10.3390/cancers15020390] [Reference Citation Analysis]
|
| 63 |
Wu ZQ, Cheng J, Xiao XX, Zhang HR, Wang J, Peng J, Liu C, Cai P, Li XM. Preoperative prediction of early recurrence of HBV-related hepatocellular carcinoma (≤5 cm) by visceral adipose tissue index. Front Surg 2022;9:985168. [PMID: 36684155 DOI: 10.3389/fsurg.2022.985168] [Reference Citation Analysis]
|
| 64 |
Visco Comandini U. Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_22] [Reference Citation Analysis]
|
| 65 |
Tse JR, Shen L, Tiyarattanachai T, Bird KN, Liang T, Yoon L, Kamaya A. Positive predictive value of LI-RADS US-3 observations: multivariable analysis of clinical and imaging features. Abdom Radiol (NY) 2023;48:271-81. [PMID: 36253490 DOI: 10.1007/s00261-022-03681-4] [Reference Citation Analysis]
|
| 66 |
Mohamed AA, Esmail OE, Ibrahim AMA, Makled S, Al-Hussain E, Elsaid A, Alboraie M, El-Awady RR. The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients. J Med Virol 2023;95:e28343. [PMID: 36424348 DOI: 10.1002/jmv.28343] [Reference Citation Analysis]
|
| 67 |
Sun Z, Fu B, Wang G, Zhang L, Xu R, Zhang Y, Lu H. High-throughput site-specific N-glycoproteomics reveals glyco-signatures for liver disease diagnosis. Natl Sci Rev 2023;10:nwac059. [PMID: 36879659 DOI: 10.1093/nsr/nwac059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 68 |
Joo I, Lee JM, Koh YH, Choi SH, Lee S, Chung JW. 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Imaging Diagnosis of Hepatocellular Carcinoma: What's New? Korean J Radiol 2023;24:1-5. [PMID: 36606612 DOI: 10.3348/kjr.2022.0538] [Reference Citation Analysis]
|
| 69 |
Qiao W, Wang Q, Mei T, Wang Q, Wang W, Zhang Y. External validation and improvement of the scoring system for predicting the prognosis in hepatocellular carcinoma after interventional therapy. Front Surg 2023;10:1045213. [PMID: 36936655 DOI: 10.3389/fsurg.2023.1045213] [Reference Citation Analysis]
|
| 70 |
De Carlis R, Lauterio A, Ficarelli A, Vella I, De Carlis L. “Re-Do” Surgery for Hepatocellular Carcinoma: Indications and Results. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_18] [Reference Citation Analysis]
|
| 71 |
Nakatsuka T, Tateishi R. Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin Mol Hepatol 2023;29:51-64. [PMID: 35903020 DOI: 10.3350/cmh.2022.0095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 72 |
Zheng Z, Hu Y, Ren Y, Mo G, Wan H. Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study. PLoS One 2023;18:e0267809. [PMID: 36706100 DOI: 10.1371/journal.pone.0267809] [Reference Citation Analysis]
|
| 73 |
Ibrahim J, Peeters M, Van Camp G, Op de Beeck K. Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. Eur J Cancer 2023;178:91-113. [PMID: 36427394 DOI: 10.1016/j.ejca.2022.10.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Shi K, Li P, Zhang Q, Zhang Y, Bi Y, Zeng X, Wang X. Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals. Front Oncol 2023;13:1128062. [PMID: 36874109 DOI: 10.3389/fonc.2023.1128062] [Reference Citation Analysis]
|
| 75 |
Kim YY, Choi JY. [CT/MRI Liver Imaging Reporting and Data System (LI-RADS): Standardization, Evidence, and Future Direction]. J Korean Soc Radiol 2023;84:15-33. [PMID: 36818714 DOI: 10.3348/jksr.2022.0144] [Reference Citation Analysis]
|
| 76 |
Guglielmo N, Colasanti M, Ferretti S, Vennarecci G, Ettorre GM. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_17] [Reference Citation Analysis]
|
| 77 |
Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X, Cheng L, Du H, Shao X, Diao Z, Hao Y, Zheng X, Li C, Li W. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula. Cancer Biol Ther 2022;23:89-95. [PMID: 35230928 DOI: 10.1080/15384047.2021.2020059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 78 |
Li Q, Cao M, Lei L, Yang F, Li H, Yan X, He S, Zhang S, Teng Y, Xia C, Chen W. Burden of liver cancer: From epidemiology to prevention. Chin J Cancer Res 2022;34:554-66. [PMID: 36714347 DOI: 10.21147/j.issn.1000-9604.2022.06.02] [Reference Citation Analysis]
|
| 79 |
Wang J, Wu R, Sun JY, Lei F, Tan H, Lu X. An overview: Management of patients with advanced hepatocellular carcinoma. Biosci Trends 2022;16:405-25. [PMID: 36476621 DOI: 10.5582/bst.2022.01109] [Reference Citation Analysis]
|
| 80 |
Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e32390. [PMID: 36595819 DOI: 10.1097/MD.0000000000032390] [Reference Citation Analysis]
|
| 81 |
Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers (Basel) 2022;15. [PMID: 36612046 DOI: 10.3390/cancers15010050] [Reference Citation Analysis]
|
| 82 |
Xu S, Huang J, Xun Z, Li S, Fu Y, Lin N, Wu W, Chen T, Liu C, Ou Q. IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro. Microbiol Spectr 2022;10:e0155722. [PMID: 36314949 DOI: 10.1128/spectrum.01557-22] [Reference Citation Analysis]
|
| 83 |
Huang Y, Zhang L, He M, Lai Z, Bu X, Wen D, Li Q, Xu L, Wei W, Zhang Y, Zhou Z, Chen M, Guo R, Shi M, Kan A. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Technol Cancer Res Treat 2022;21:15330338221117389. [PMID: 36529949 DOI: 10.1177/15330338221117389] [Reference Citation Analysis]
|
| 84 |
Hsu PY, Liang PC, Chang WT, Lu MY, Wang WH, Chuang SC, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Chuang WL, Huang CF, Huang JF, Yu ML. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma. Am J Cancer Res 2022;12:5576-88. [PMID: 36628276] [Reference Citation Analysis]
|
| 85 |
Huang Z, Shu Z, Zhu RH, Xin JY, Wu LL, Wang HZ, Chen J, Zhang ZW, Luo HC, Li KY. Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(12): 2380-2392 [DOI: 10.4251/wjgo.v14.i12.2380] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 86 |
Samarasinghe SM, Hewage AS, Siriwardena R, Tennekoon KH, Niriella MA, de Silva S, Viswakula SD. Association and impact of SNPs in PNPLA3, TM6SF2 and MBOAT7 genes on prognosis factors of hepatocellular carcinoma with non-viral etiology.. [DOI: 10.21203/rs.3.rs-2336549/v1] [Reference Citation Analysis]
|
| 87 |
Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, Müller M, Kandulski A. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines 2022;10. [PMID: 36551958 DOI: 10.3390/biomedicines10123202] [Reference Citation Analysis]
|
| 88 |
Zhou R, Ni W, Qin C, Zhou Y, Li Y, Huo J, Bian L, Zhou A, Li J. A functional loop between YTH domain family protein YTHDF3 mediated m(6)A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:334. [PMID: 36471428 DOI: 10.1186/s13046-022-02538-4] [Reference Citation Analysis]
|
| 89 |
Cassese G, Han HS, Cho JY, Lee HW, Lee B, Troisi RI. Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36497478 DOI: 10.3390/cancers14235997] [Reference Citation Analysis]
|
| 90 |
Han S, Lee JM, Kim SW, Park S, Nickel MD, Yoon JH. Evaluation of HASTE T2 weighted image with reduced echo time for detecting focal liver lesions in patients at risk of developing hepatocellular carcinoma. European Journal of Radiology 2022;157:110588. [DOI: 10.1016/j.ejrad.2022.110588] [Reference Citation Analysis]
|
| 91 |
Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto R, Tanaka H, Kobayashi Y, Mizuno S, Nakagawa H. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment. Eur J Gastroenterol Hepatol 2022;34:1269-76. [PMID: 36317773 DOI: 10.1097/MEG.0000000000002459] [Reference Citation Analysis]
|
| 92 |
Chang JI, Sinn DH, Jeong WK, Hwang JA, Won HY, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scand J Gastroenterol 2022;57:1470-7. [PMID: 35786290 DOI: 10.1080/00365521.2022.2093124] [Reference Citation Analysis]
|
| 93 |
Jearth V, Patil PS, Mehta S, Goel M, Patkar S, Kulkarni S, Shetty N, Ostwal V, Ramaswamy A, Sastri S, Engineer R. A study of the clinical profile, predictors, prognostic features, and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis. Indian J Gastroenterol 2022;41:533-43. [PMID: 36715840 DOI: 10.1007/s12664-022-01289-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 94 |
Lv JH, Chen WZ, Li YN, Wang JX, Fu YK, Zeng ZX, Wu JY, Wang SJ, Huang XX, Huang LM, Huang RF, Wei YG, Yan ML. Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study. HPB (Oxford) 2022;24:2175-84. [PMID: 36280426 DOI: 10.1016/j.hpb.2022.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 95 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 96 |
Liu J, Li L, Zeng Q, Zheng R, Li K. Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study. Abdom Radiol (NY) 2022;47:4245-53. [PMID: 36121457 DOI: 10.1007/s00261-022-03631-0] [Reference Citation Analysis]
|
| 97 |
Chang SS, Hu HY, Cheng FS, Chen YC, Yen YF, Huang N. Factors associated with nonadherence to surveillance for hepatocellular carcinoma among patients with hepatic C virus cirrhosis, 2000-2015. Medicine (Baltimore) 2022;101:e31907. [PMID: 36451463 DOI: 10.1097/MD.0000000000031907] [Reference Citation Analysis]
|
| 98 |
Sun F, Li Z, Hu L, Deng W, Jiang T, Wang S, Bi X, Lu H, Yang L, Lin Y, Zeng Z, Shen G, Liu R, Chang M, Wu S, Gao Y, Hao H, Xu M, Chen X, Zhang L, Lu Y, Dong J, Xie Y, Li M. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection. Front Immunol 2022;13:1082091. [PMID: 36505492 DOI: 10.3389/fimmu.2022.1082091] [Reference Citation Analysis]
|
| 99 |
Li G, Shu B, Zheng Z, Yin H, Zhang C, Xiao Y, Yang Y, Yan Z, Zhang X, Yang S, Li G, Dong J. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial. Front Oncol 2022;12:1051916. [PMID: 36505833 DOI: 10.3389/fonc.2022.1051916] [Reference Citation Analysis]
|
| 100 |
Wang P, Song Q, Ren J, Zhang W, Wang Y, Zhou L, Wang D, Chen K, Jiang L, Zhang B, Chen W, Qu C, Zhao H, Jiao Y. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Sci Transl Med 2022;14:eabp8704. [PMID: 36417488 DOI: 10.1126/scitranslmed.abp8704] [Reference Citation Analysis]
|
| 101 |
Zhang S, Huo L, Feng Y, Zhang J, Wu Y, Liu Y, Lu L, Jia N, Liu W. Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI. Front Oncol 2022;12:986713. [PMID: 36505850 DOI: 10.3389/fonc.2022.986713] [Reference Citation Analysis]
|
| 102 |
Köpping-segerling CC, Pohl M, Canbay A, Best J. Hepatozelluläres Karzinom – Screening und Surveillance. Gastroenterologie 2022. [DOI: 10.1007/s11377-022-00651-6] [Reference Citation Analysis]
|
| 103 |
Nguyen-Dinh SH, Li WF, Liu YW, Wang CC, Chen YH, Wang JH, Hung CH. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. Viruses 2022;14. [PMID: 36423180 DOI: 10.3390/v14112571] [Reference Citation Analysis]
|
| 104 |
Wang P, Yang S, Li C, Han X, Hong D, Shao H. Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma. BMC Cancer 2022;22:1177. [DOI: 10.1186/s12885-022-10290-3] [Reference Citation Analysis]
|
| 105 |
Wang L, Zeng Q, Jiang S, Chen Z, Wang X, Li L, Li X. Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.987481] [Reference Citation Analysis]
|
| 106 |
Chen Y, Wang C, Chen Y, Wang J, Hung C, Kuo Y. Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer 2022;22:1153. [DOI: 10.1186/s12885-022-10271-6] [Reference Citation Analysis]
|
| 107 |
Kang HJ, Lee JM, Yoon JH, Yoo J, Choi Y, Joo I, Han JK. Sonazoid™ versus SonoVue(®) for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. Korean J Radiol 2022;23:1067-77. [PMID: 36196767 DOI: 10.3348/kjr.2022.0388] [Reference Citation Analysis]
|
| 108 |
Shuai Zhang, Chongfeng Duan, Xiaoming Zhou, Fang Liu, Xin Wang, Qiulin Shao, Yuanxiang Gao, Feng Duan, Ruirui Zhao, Gang Wang. Radiomics nomogram for prediction of microvascular invasion in hepatocellular carcinoma based on MR imaging with Gd-EOB-DTPA. Front Oncol 2022;12:1034519. [PMID: 36387156 DOI: 10.3389/fonc.2022.1034519] [Reference Citation Analysis]
|
| 109 |
Ge C, Luo M, Guo K, Zhu D, Han N, Wang T, Zhao X. Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: a large-scale real-world study. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.11.003] [Reference Citation Analysis]
|
| 110 |
Pan J, Li W, Gu L, Liu C, Zhang K, Hong G. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis. Eur Radiol 2022;32:7883-95. [PMID: 35579711 DOI: 10.1007/s00330-022-08826-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Zhu HD, Li X, Ji JS, Huang M, Shao GL, Lu J, Zhao XY, Li HL, Yang ZQ, Tu JF, Zhou JM, Zeng CH, Teng GJ. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. Eur Radiol 2022;32:7335-43. [PMID: 35776182 DOI: 10.1007/s00330-022-08848-7] [Reference Citation Analysis]
|
| 112 |
Sy AM, Ferreira RD, John BV. Hepatocellular Carcinoma in Primary Biliary Cholangitis. Clin Liver Dis 2022;26:691-704. [PMID: 36270724 DOI: 10.1016/j.cld.2022.06.011] [Reference Citation Analysis]
|
| 113 |
Lee TH, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, Ronald J. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Dig Dis Sci 2022;67:5345-52. [PMID: 35257246 DOI: 10.1007/s10620-022-07428-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 114 |
Inmutto N, Nimitrungtawee N, Srisuwan T, Kattipathanapong T, Jantarangkoon A, Puttisri O. Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization. Asian Pac J Cancer Prev 2022;23:3939-46. [PMID: 36444608 DOI: 10.31557/APJCP.2022.23.11.3939] [Reference Citation Analysis]
|
| 115 |
Tse JR, Shen L, Bird KN, Yoon L, Kamaya A. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound. AJR Am J Roentgenol 2022;219:774-83. [PMID: 35703411 DOI: 10.2214/AJR.22.27812] [Reference Citation Analysis]
|
| 116 |
Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mähringer‐kunz A, Paisant A, Renzulli M, Schima W, Terraz S, Valls C, Wagner M, Ayuso C, Vilgrain V, Reig M, Ronot M. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology 2022;76:1318-1328. [DOI: 10.1002/hep.32494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 117 |
Choi J. Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection". J Hepatol 2022;77:1472-4. [PMID: 35987276 DOI: 10.1016/j.jhep.2022.07.032] [Reference Citation Analysis]
|
| 118 |
Zhang K, Ye T, Lu W, Xu F, Xie Y, Wang D, Xiao Z, Liu S, Yao W, Cheng J, Shen G, Liu J, Zhang C, Huang D, Liang L. Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. Front Oncol 2022;12:1042869. [DOI: 10.3389/fonc.2022.1042869] [Reference Citation Analysis]
|
| 119 |
Gao X, Tang H, Wang J, Yao Q, Wang H, Wang Y, Ma M, Yang W, Yan K, Wu W. Specific imaging features indicate the clinical features of patients with hepatic perivascular epithelioid cell tumor by comparative analysis of CT and ultrasound imaging. Front Oncol 2022;12:908189. [DOI: 10.3389/fonc.2022.908189] [Reference Citation Analysis]
|
| 120 |
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400:1345-62. [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 121 |
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. Sci Rep 2022;12:17018. [PMID: 36220865 DOI: 10.1038/s41598-022-21528-2] [Reference Citation Analysis]
|
| 122 |
Sultan LR, Al-hasani M, Karmacharya MB, Cary TW, Sehgal CM. Contrast-enhanced ultrasound for assessing blood flow modulation of hepatocellular carcinoma by hydralazine. 2022 IEEE International Ultrasonics Symposium (IUS) 2022. [DOI: 10.1109/ius54386.2022.9958467] [Reference Citation Analysis]
|
| 123 |
Liang Z, Liu L, Guo X, Wu X, Yu Y, Yu Z, Hu X, Zhang X, Wang J. The expression profiles of circular RNAs and competing endogenous RNA networks in intrahepatic cholangiocarcinoma. Front Cell Dev Biol 2022;10:942853. [DOI: 10.3389/fcell.2022.942853] [Reference Citation Analysis]
|
| 124 |
Matthias Buechter, Guido Gerken. Liver Function—How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. J Pers Med 2022;12:1657. [PMID: 36294796 DOI: 10.3390/jpm12101657] [Reference Citation Analysis]
|
| 125 |
Lee HW, Kim E, Cho KJ, Park HJ, Seo J, Lee H, Baek E, Choi JR, Han KH, Lee ST, Park JY. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. Liver Int 2022;42:2317-26. [PMID: 35776657 DOI: 10.1111/liv.15356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 126 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 127 |
Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol 2022;28:851-63. [PMID: 36263667 DOI: 10.3350/cmh.2022.0037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 128 |
Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2022;46:101799. [PMID: 34500120 DOI: 10.1016/j.clinre.2021.101799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 129 |
Braga FA, Torres US, Iared W, D´ippolito G. Does hypointense HCC in the Hepatobiliary Phase at Gadoxetate-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis. Academic Radiology 2022. [DOI: 10.1016/j.acra.2022.09.015] [Reference Citation Analysis]
|
| 130 |
Liu SY, Li C, Sun LY, Guan MC, Gu LH, Yin DX, Yao LQ, Liang L, Wang MD, Xing H, Zhu H, Pawlik TM, Lau WY, Shen F, Tong XM, Yang T. ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis. Front Oncol 2022;12:1018396. [PMID: 36263214 DOI: 10.3389/fonc.2022.1018396] [Reference Citation Analysis]
|
| 131 |
Li W, Shen H, Han L, Liu J, Xiao B, Li X, Ye Z, Kolla J. A Multiparametric Fusion Radiomics Signature Based on Contrast-Enhanced MRI for Predicting Early Recurrence of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/3704987] [Reference Citation Analysis]
|
| 132 |
Wang W, Deng ZF, Wang JL, Zhang L, Bao L, Xu BH, Zhu H, Guo Y, Wen Z. Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma. World J Gastrointest Surg 2022; 14(9): 1008-1025 [DOI: 10.4240/wjgs.v14.i9.1008] [Reference Citation Analysis]
|
| 133 |
Ding J, Zhao W. The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2735-48. [PMID: 36133739 DOI: 10.2147/CMAR.S373165] [Reference Citation Analysis]
|
| 134 |
Mohamed EA, Giama NH, Abdalla AO, Shaleh HM, Oseini AM, Ali HA, Ahmed F, Taha W, Ahmed Mohammed H, Cvinar J, Waaeys IA, Ali H, Allotey LK, Ali AO, Mohamed SA, Harmsen WS, Ahmmad EM, Bajwa NA, Afgarshe MD, Shire AM, Balls-Berry JE, Roberts LR. High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol 2022; 28(35): 5217-5229 [DOI: 10.3748/wjg.v28.i35.5217] [Reference Citation Analysis]
|
| 135 |
Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. Br J Radiol 2022;95:20220379. [PMID: 35867889 DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 136 |
Garcia-Monaco RD, Chung JW, Vilgrain V, Bouattour M, Covey AM. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol 2022;95:20220179. [PMID: 35848758 DOI: 10.1259/bjr.20220179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 137 |
Solbiati LA, Arai Y. Interventional oncology of liver tumors: how it all started and where are we now. Br J Radiol 2022;95:20220434. [PMID: 35776630 DOI: 10.1259/bjr.20220434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 138 |
Lee J, Park SB, Byun S, Kim HI. Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance. PLoS ONE 2022;17:e0274747. [DOI: 10.1371/journal.pone.0274747] [Reference Citation Analysis]
|
| 139 |
Liu Y, Liu L. Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. Cancers 2022;14:4473. [DOI: 10.3390/cancers14184473] [Reference Citation Analysis]
|
| 140 |
Brozzetti S, D'Alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients-A Retrospective Observational Study. Cancers (Basel) 2022;14. [PMID: 36139581 DOI: 10.3390/cancers14184422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Ni Z, Wu B, Liu Z, Wang Q, Han X, Cheng W, Guo C. Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting the prognosis of hepatocellular carcinoma after radiofrequency ablation.. [DOI: 10.21203/rs.3.rs-2013292/v1] [Reference Citation Analysis]
|
| 142 |
Prasoppokakorn T, Thanapirom K, Treeprasertsuk S. Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma. Case Reports in Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/5101856] [Reference Citation Analysis]
|
| 143 |
Fraquelli M, Nadarevic T, Colli A, Manzotti C, Giljaca V, Miletic D, Štimac D, Casazza G. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;9:CD013483. [PMID: 36053210 DOI: 10.1002/14651858.CD013483.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 144 |
Hashimoto R, Himoto T, Yamada M, Mimura S, Fujita K, Tani J, Morishita A, Masaki T. Antitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of Apoptosis. J Nutr Sci Vitaminol (Tokyo) 2022;68:303-11. [PMID: 36047102 DOI: 10.3177/jnsv.68.303] [Reference Citation Analysis]
|
| 145 |
Guo D, Qin L, Sun J, Li K, Zang C, Wang Q, Qiao W, Liu B, Zhao Y, Zhang Y. Dynamic changes in cytokine profiles and their impact on tumour recurrence following thermal ablation in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-1998332/v1] [Reference Citation Analysis]
|
| 146 |
Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
|
| 147 |
Moon AM, Ioannou GN. Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. Am J Gastroenterol 2022;117:1409-11. [PMID: 35973179 DOI: 10.14309/ajg.0000000000001897] [Reference Citation Analysis]
|
| 148 |
Rao H, Shang J, Xie Q, Lian J, Gao P, Shi J, Chen X, Wang J, Xu M, Zhang L, Zhao Y, Mao Q, Wang M, Zhao W, Zhang Z, Jia J, Tang H, Zhang J, Zheng X, Liu C, Wei L. Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis. iLIVER 2022;1:145-153. [DOI: 10.1016/j.iliver.2022.08.006] [Reference Citation Analysis]
|
| 149 |
Liu S, Sun L, Yao L, Zhu H, Diao Y, Wang M, Xing H, Lau WY, Guan M, Pawlik TM, Shen F, Xu M, Tong X, Yang T. Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. J Clin Med 2022;11. [PMID: 36079006 DOI: 10.3390/jcm11175075] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Li Z, Cheng H, Mao J, Liu G. Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology. Sci China Life Sci 2022. [DOI: 10.1007/s11427-022-2142-3] [Reference Citation Analysis]
|
| 151 |
Yuan M, Chen TY, Chen XR, Lu YF, Shi J, Zhang WS, Ye C, Tang BZ, Yang ZG. Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study. World J Clin Cases 2022; 10(24): 8535-8546 [DOI: 10.12998/wjcc.v10.i24.8535] [Reference Citation Analysis]
|
| 152 |
Heo J, Joung C, Pahk K, Pahk KJ. Investigation of the long-term healing response of the liver to boiling histotripsy treatment in vivo. Sci Rep 2022;12:14462. [PMID: 36002564 DOI: 10.1038/s41598-022-18544-7] [Reference Citation Analysis]
|
| 153 |
Wang T, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Smith DA, Salih H, Campbell C, Freeman O, Harris S, Várnai KA, Roadknight G, Little S, Noble T, Woods K, Matthews PC, Davies J, Cooke GS, Barnes E, NIHR Health Informatics Collaborative Viral Hepatitis Theme Consortium. Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records.. [DOI: 10.1101/2022.08.23.22279119] [Reference Citation Analysis]
|
| 154 |
Liu YS, Chang PY, Liang PC, Ou MC, Hwang JI, Chen CH. Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). J Hepatocell Carcinoma 2022;9:811-21. [PMID: 35996398 DOI: 10.2147/JHC.S374555] [Reference Citation Analysis]
|
| 155 |
Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R, Yoshikawa K, Tempaku M, Sakaguchi K, Tanaka H, Sugimoto K, Kobayashi Y, Yamaguchi T, Nakagawa H. The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. Front Oncol 2022;12:993705. [DOI: 10.3389/fonc.2022.993705] [Reference Citation Analysis]
|
| 156 |
Kim SK, Fujii T, Kim SR, Nakai A, Lim YS, Hagiwara S, Kudo M. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus. Liver Cancer 2022;11:497-510. [PMID: 36589728 DOI: 10.1159/000525518] [Reference Citation Analysis]
|
| 157 |
Chen YD, Zhang L, Zhou ZP, Lin B, Jiang ZJ, Tang C, Dang YW, Xia YW, Song B, Long LL. Radiomics and nomogram of magnetic resonance imaging for preoperative prediction of microvascular invasion in small hepatocellular carcinoma. World J Gastroenterol 2022; 28(31): 4399-4416 [DOI: 10.3748/wjg.v28.i31.4399] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 158 |
Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current Imaging Diagnosis of Hepatocellular Carcinoma. Cancers 2022;14:3997. [DOI: 10.3390/cancers14163997] [Reference Citation Analysis]
|
| 159 |
Tseng CW, Liu WC, Ko PH, Chen YC, Tseng KC, Chang TT. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients. Viruses 2022;14. [PMID: 36016434 DOI: 10.3390/v14081812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res 2022;10:59. [PMID: 35971182 DOI: 10.1186/s40364-022-00406-z] [Reference Citation Analysis]
|
| 161 |
Wang J, Li S. Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis. Front Med 2022;9. [DOI: 10.3389/fmed.2022.946100] [Reference Citation Analysis]
|
| 162 |
Malik J, Klammer M, Rolny V, Chan HLY, Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, Swiatek-de Lange M. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. World J Gastroenterol 2022; 28(29): 3917-3933 [DOI: 10.3748/wjg.v28.i29.3917] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 163 |
Li N, Zheng H, Yu Q, Chen F, Su X, Qiu X. Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. J Int Med Res 2022;50:030006052211152. [DOI: 10.1177/03000605221115251] [Reference Citation Analysis]
|
| 164 |
Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2022;42:2067-79. [PMID: 34515412 DOI: 10.1111/liv.15052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 165 |
Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Curr Opin Organ Transplant 2022;27:312-9. [PMID: 36354257 DOI: 10.1097/MOT.0000000000000997] [Reference Citation Analysis]
|
| 166 |
Hidaka M, Hara T, Soyama A, Adachi T, Matsushima H, Tanaka T, Ishimaru H, Miyaaki H, Nakao K, Eguchi S. Long‐term outcomes of living‐donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3‐cm nodules in a single institute. JGH Open 2022;6:539-546. [DOI: 10.1002/jgh3.12783] [Reference Citation Analysis]
|
| 167 |
Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int 2022;42:2042-54. [PMID: 34894051 DOI: 10.1111/liv.15130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 168 |
Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2022;42:1955-68. [PMID: 34459096 DOI: 10.1111/liv.15046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 169 |
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 170 |
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol 2022;57:587-97. [PMID: 35788887 DOI: 10.1007/s00535-022-01893-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 171 |
Yang SB, Zhang JH, Fu YF, Wang R. TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis. Minim Invasive Ther Allied Technol 2022;31:856-64. [PMID: 35238280 DOI: 10.1080/13645706.2022.2045326] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 172 |
Nakano M, Torisu Y, Nakagawa C, Ueda K, Kanai T, Saeki C, Oikawa T, Saruta M. Safety and efficacy of pentazocine–midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma. JGH Open 2022;6:569-576. [DOI: 10.1002/jgh3.12788] [Reference Citation Analysis]
|
| 173 |
Huang J, Zhong J, Zhang J, Gong W, Ma L, Li L, Xiang B. Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol.. [DOI: 10.1101/2022.07.29.22278175] [Reference Citation Analysis]
|
| 174 |
Pagano D, Khouzam S, Magro B, Barbara M, Cintorino D, di Francesco F, Li Petri S, Bonsignore P, Calamia S, Deiro G, Cammà C, Canzonieri M, Gruttadauria S. How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation? Front Oncol 2022;12:929607. [DOI: 10.3389/fonc.2022.929607] [Reference Citation Analysis]
|
| 175 |
Qian X, Liu Y, Wu F, Zhang S, Gong J, Nan Y, Hu B, Chen J, Zhao J, Chen X, Pan W, Dang S, Lu F. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients. Viruses 2022;14. [PMID: 36016291 DOI: 10.3390/v14081669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 176 |
Renzulli M, Pecorelli A, Brandi N, Brocchi S, Tovoli F, Granito A, Carrafiello G, Ierardi AM, Golfieri R. The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool? JCM 2022;11:4399. [DOI: 10.3390/jcm11154399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 177 |
Fernandes DA, Dal Lago EA, Oliver FA, Loureiro BMC, Martins DL, Penachim TJ, Barros RHO, Araújo Filho JAB, Eloy da Costa LB, da Silva ÁMO, de Ataíde EC, Boin IFSF, Caserta NMG. Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice. World J Hepatol 2022;14:1459-69. [PMID: 36158916 DOI: 10.4254/wjh.v14.i7.1459] [Reference Citation Analysis]
|
| 178 |
Beal EW, Owen M, McNamara M, McAlearney AS, Tsung A. Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review. J Gastrointest Cancer 2022. [PMID: 35879510 DOI: 10.1007/s12029-022-00851-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Ma Y, Liu G, Yang J, Li X, Yang X, Fang S, Zhao B. The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma. Contrast Media Mol Imaging 2022;2022:9316873. [PMID: 35800233 DOI: 10.1155/2022/9316873] [Reference Citation Analysis]
|
| 180 |
Lu W, Wang L, Lou J, Tang K. Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. Tumori 2022;:3008916221110265. [PMID: 35815545 DOI: 10.1177/03008916221110265] [Reference Citation Analysis]
|
| 181 |
Zhu L, Zhang Y, Li Y, Wang H, Shen G, Wang Z. Inhibitory effect of lingonberry extract on HepG2 cell proliferation, apoptosis, migration, and invasion. PLoS ONE 2022;17:e0270677. [DOI: 10.1371/journal.pone.0270677] [Reference Citation Analysis]
|
| 182 |
Chen SH, Lai HC, Su WP, Kao JT, Chuang PH, Hsu WF, Wang HW, Hsieh TL, Chen HY, Peng CY. Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C. Can J Gastroenterol Hepatol 2022;2022:5201443. [PMID: 35837486 DOI: 10.1155/2022/5201443] [Reference Citation Analysis]
|
| 183 |
Celik F, Bektas H. The role of nursing in the hepatic rehabilitation of patients with liver cirrhosis. Gastrointestinal Nursing 2022;20:S18-S25. [DOI: 10.12968/gasn.2022.20.sup6.s18] [Reference Citation Analysis]
|
| 184 |
Ghamari SH, Yoosefi M, Abbasi-Kangevari M, Malekpour MR, Saeedi Moghaddam S, Shahin S, Esfahani Z, Koolaji S, Shobeiri P, Ghaffari A, Sohrabi H, Kazemi A, Rezaei N, Larijani B, Farzadfar F. Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019. Hepatol Commun 2022;6:1764-75. [PMID: 35134275 DOI: 10.1002/hep4.1910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 185 |
Tsai MC, Yang SS, Lin CC, Wang WL, Hsu YC, Chen YS, Hu JT, Lin JY, Yu ML, Lin CW. Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. JAMA Netw Open 2022;5:e2223511. [PMID: 35877121 DOI: 10.1001/jamanetworkopen.2022.23511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022;6:1753-63. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 187 |
Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, Alatise IO, Okello M, Blondel NO, Mulehane KO, Abubeker ZA, Nogoud AA, Nashidengo PR, Chihaka O, Tzeuton C, Dusheiko G, Sonderup M, Spearman CW. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00042-5] [Reference Citation Analysis]
|
| 188 |
Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022;6:1813-26. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 189 |
Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2022;54:927-36. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 190 |
Chen ZH, Zhang XP, Feng JK, Li LQ, Zhang F, Hu YR, Zhong CQ, Wang K, Chai ZT, Wei XB, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. HPB (Oxford) 2022;24:1063-73. [PMID: 34961677 DOI: 10.1016/j.hpb.2021.11.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 191 |
Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022;47:2299-313. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
|
| 192 |
Wang Y, Li X, Yu J, Cheng Z, Hou Q, Liang P. Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878737] [Reference Citation Analysis]
|
| 193 |
Wang L, Ma X, Feng B, Wang S, Liang M, Li D, Wang S, Zhao X. Multi-Sequence MR-Based Radiomics Signature for Predicting Early Recurrence in Solitary Hepatocellular Carcinoma ≤5 cm. Front Oncol 2022;12:899404. [PMID: 35756618 DOI: 10.3389/fonc.2022.899404] [Reference Citation Analysis]
|
| 194 |
Xie Z, Peng Z, Zou Y, Xiao H, Li B, Zhou Q, Chen S, Xu L, Shen J, Mo Y, Peng S, Kuang M, Long J, Feng ST. Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population. BMC Cancer 2022;22:709. [PMID: 35761201 DOI: 10.1186/s12885-022-09812-w] [Reference Citation Analysis]
|
| 195 |
Lu Q, Long Y, Fan K, Shen Z, Gai Y, Liu Q, Jiang D, Cai W, Wan C, Lan X. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. Eur J Nucl Med Mol Imaging 2022. [PMID: 35763056 DOI: 10.1007/s00259-022-05884-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 196 |
Peng Y, Chen K, Li B, Xu H, Wei Y, Liu F. Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. Updates Surg 2022. [PMID: 35739381 DOI: 10.1007/s13304-022-01309-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 197 |
Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
|
| 198 |
Zhang H, Jiang PJ, Lv MY, Zhao YH, Cui J, Chen J. OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells. J Clin Lab Anal 2022;:e24561. [PMID: 35723423 DOI: 10.1002/jcla.24561] [Reference Citation Analysis]
|
| 199 |
Hwang JA, Jeong WK, Kang HJ, Lee ES, Park HJ, Lee JM. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma. Eur Radiol 2022. [PMID: 35705829 DOI: 10.1007/s00330-022-08900-6] [Reference Citation Analysis]
|
| 200 |
Zhou D, Wang Y, Hu H, Liu H, Deng J, Li L, Zheng C. lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound. World J Surg Oncol 2022;20:203. [PMID: 35706002 DOI: 10.1186/s12957-022-02655-6] [Reference Citation Analysis]
|
| 201 |
Xu MH, Xu B, Zhou CH, Xue Z, Chen ZS, Xu WX, Huang C, Zhu XD, Zhou J, Fan J, Sun HC, Shen YH. An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study. World J Surg Oncol 2022;20:206. [PMID: 35710377 DOI: 10.1186/s12957-022-02672-5] [Reference Citation Analysis]
|
| 202 |
Kale A. Hepatocellular Carcinoma: Diagnosis and Surveillance. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99839] [Reference Citation Analysis]
|
| 203 |
Giakoustidis A, Koffas A, Giakoustidis D, N. Papadopoulos V. Minimally Invasive Surgery for Hepatocellular Carcinoma; Latest Advances. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99840] [Reference Citation Analysis]
|
| 204 |
Mo Q, Liu Y, Zhou Z, Li R, Gong W, Xiang B, Tang W, Yu H. Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. Front Oncol 2022;12:876900. [PMID: 35664791 DOI: 10.3389/fonc.2022.876900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 205 |
Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
|
| 206 |
Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
|
| 207 |
Shen Y, Huang C, Zhu X, Xu M, Chen Z, Tan C, Zhou J, Fan J, Sun H. The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. Annals of Surgery Open 2022;3:e163. [DOI: 10.1097/as9.0000000000000163] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 208 |
Kim AK, Hamilton JP, Lin SY, Chang TT, Hann HW, Hu CT, Lou Y, Lin YJ, Gade TP, Park G, Luu H, Lee TJ, Wang J, Chen D, Goggins MG, Jain S, Song W, Su YH. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer 2022;126:1432-8. [PMID: 35046521 DOI: 10.1038/s41416-022-01706-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 209 |
Alzoubi O, Arar A, Singh V, Erturk SM, Mozes F, Pavlides M. MRI in liver cirrhosis. Portal Hypertension & Cirrhosis 2022;1:23-41. [DOI: 10.1002/poh2.6] [Reference Citation Analysis]
|
| 210 |
Liu X, Wang X, Yu L, Hou Y, Jiang Y, Wang X, Han J, Yang Z. A Novel Prognostic Score Based on Artificial Intelligence in Hepatocellular Carcinoma: A Long-Term Follow-Up Analysis. Front Oncol 2022;12:817853. [DOI: 10.3389/fonc.2022.817853] [Reference Citation Analysis]
|
| 211 |
Khan W, Ahmad W, Hashem AM, Zakai S, Haque S, Malik MFA, Harakeh S, Haq F. Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. JCM 2022;11:3093. [DOI: 10.3390/jcm11113093] [Reference Citation Analysis]
|
| 212 |
Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(20): 2176-2183 [DOI: 10.3748/wjg.v28.i20.2176] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 213 |
Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers 2022;14:2549. [DOI: 10.3390/cancers14102549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 214 |
Rattananukrom C, Kitiyakara T. Comparison between using hepatocellular carcinoma ( HCC ) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand. JGH Open. [DOI: 10.1002/jgh3.12753] [Reference Citation Analysis]
|
| 215 |
Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 216 |
Yu R, Cao Z, Huang Y, Zhang X, Chen J, Li Y. Establishment and Analysis of a Combined Diagnostic Model of Liver Cancer with Random Forest and Artificial Neural Network. Mathematical Problems in Engineering 2022;2022:1-17. [DOI: 10.1155/2022/5679837] [Reference Citation Analysis]
|
| 217 |
Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M, Piratvisuth T. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. [DOI: 10.1002/jgh3.12720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 218 |
Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019 [DOI: 10.12998/wjcc.v10.i13.3989] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 219 |
Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 220 |
Lin X, Xiao M, Gu YJ, Zhu HK, Li MX, Zhuang L, Zheng SS, Li QY. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00120-5. [PMID: 35568681 DOI: 10.1016/j.hbpd.2022.05.002] [Reference Citation Analysis]
|
| 221 |
Burciu C, Șirli R, Bende F, Fofiu R, Popescu A, Sporea I, Ghiuchici AM, Miuțescu B, Dănilă M. Usefulness of Imaging and Biological Tools for the Characterization of Portal Vein Thrombosis in Hepatocellular Carcinoma. Diagnostics (Basel) 2022;12. [PMID: 35626300 DOI: 10.3390/diagnostics12051145] [Reference Citation Analysis]
|
| 222 |
Akbulut S, Garzali IU, Hargura AS, Aloun A, Yilmaz S. Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. J Gastrointest Cancer 2022;:1-12. [PMID: 35499649 DOI: 10.1007/s12029-022-00830-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 223 |
Faria LL, Darce GF, Bordini AL, Herman P, Jeismann VB, de Oliveira IS, Ortega CD, Rocha MS. Liver Surgery: Important Considerations for Pre- and Postoperative Imaging. Radiographics 2022;42:722-40. [PMID: 35363553 DOI: 10.1148/rg.210124] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 224 |
Lebossé F, Caussy C. Editorial: screening for hepatocellular carcinoma in NAFLD-towards abbreviated MRI alternative in patients with obesity? Aliment Pharmacol Ther 2022;55:1210-1. [PMID: 35429036 DOI: 10.1111/apt.16887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 225 |
Hallemeier CL, Apisarnthanarax S, Dawson LA. BCLC 2022 update: Important advances, but missing external beam radiotherapy. J Hepatol 2022;76:1237-9. [PMID: 34990748 DOI: 10.1016/j.jhep.2021.12.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 226 |
Young Park J, Min Lee S, Sub Lee J, Chang W, Hee Yoon J. Free-breathing dynamic T1WI using compressed sensing-golden angle radial sparse parallel imaging for liver MRI in patients with limited breath-holding capability. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110342] [Reference Citation Analysis]
|
| 227 |
Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 228 |
Xu X, Sun S, Liu Q, Liu X, Wu F, Shen C. Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:1806-16. [PMID: 35267069 DOI: 10.1007/s00261-022-03473-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 229 |
Wang P, Zhang D, Fang C, Gan Y, Luo B, Yang XL, Peng FY, Li B, Su S. Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies. Eur J Surg Oncol 2022:S0748-7983(22)00412-7. [PMID: 35545472 DOI: 10.1016/j.ejso.2022.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 230 |
Li L, Zheng W, Wang J, Han J, Guo Z, Hu Y, Li X, Zhou J. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection. AJR Am J Roentgenol 2022. [PMID: 35441534 DOI: 10.2214/AJR.22.27521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 231 |
Zheng K, Liao A, Yan L, Yang J, Wen T, Wang W, Li B, Wu H, Jiang L. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 35441310 DOI: 10.1245/s10434-022-11757-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 232 |
Zhang Z, Wang F, Zhang J, Zhan W, Zhang G, Li C, Zhang T, Yuan Q, Chen J, Guo M, Xu H, Yu F, Wang H, Wang X, Kong W. An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma. Front Pharmacol 2022;13:854851. [PMID: 35431958 DOI: 10.3389/fphar.2022.854851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 233 |
Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
|
| 234 |
Xu W, Wang Y, Yang Z, Li J, Li R, Liu F. New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study. Front Oncol 2022;12:796311. [PMID: 35433417 DOI: 10.3389/fonc.2022.796311] [Reference Citation Analysis]
|
| 235 |
Cassese G, Han H, Lee B, Lee HW, Cho JY, Troisi R. Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma. Cancers 2022;14:2012. [DOI: 10.3390/cancers14082012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 236 |
Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
|
| 237 |
Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, Meng Y, Zhai J, Shan YF, Cheng SQ. Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Front Oncol 2022;12:839605. [PMID: 35387113 DOI: 10.3389/fonc.2022.839605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 238 |
Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodríguez-Tajes S, Genescà J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2022;76:812-21. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 239 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
|
| 240 |
Sato M, Kobayashi T, Soroida Y, Tanaka T, Nakatsuka T, Nakagawa H, Nakamura A, Kurihara M, Endo M, Hikita H, Sato M, Gotoh H, Iwai T, Tateishi R, Koike K, Yatomi Y. Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images. J Gastroenterol Hepatol 2022;37:678-84. [PMID: 34911147 DOI: 10.1111/jgh.15763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 241 |
Gao F, Wei Y, Zhang T, Jiang H, Li Q, Yuan Y, Yao S, Ye Z, Wan S, Wei X, Nie L, Tang H, Song B. New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Front Oncol 2022;12:812832. [PMID: 35356206 DOI: 10.3389/fonc.2022.812832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 242 |
Yan Q, Sun Y, An R, Liu F, Fang Q, Wang Z, Xu T, Chen L, Du J. Application and progress of the detection technologies in hepatocellular carcinoma. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.04.003] [Reference Citation Analysis]
|
| 243 |
Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 2022;55:820-7. [PMID: 35229334 DOI: 10.1111/apt.16844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 244 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico. Revista de Gastroenterología de México 2022;87:216-234. [DOI: 10.1016/j.rgmx.2021.10.002] [Reference Citation Analysis]
|
| 245 |
Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;22:371-81. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 246 |
Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 247 |
Hu S, Wu X, Wei M, Ling Y, Zhu M, Wang Y, Chen Y, Jin M, Peng Z. Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. J Oncol 2022;2022:3569644. [PMID: 35345515 DOI: 10.1155/2022/3569644] [Reference Citation Analysis]
|
| 248 |
Liu Z, Liu Y, Zhang W, Hong Y, Meng J, Wang J, Zheng S, Xu X. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. [DOI: 10.1007/s12072-022-10321-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 249 |
Hui RW, Chan AC, Lo G, Lo R, Chan C, Kotewall CN, Mak L, She W, Au K, Ai V, Fung J, Yuen M, Seto W. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. Hepatol Int. [DOI: 10.1007/s12072-022-10305-y] [Reference Citation Analysis]
|
| 250 |
Nicolosi A, Pellicano R, Caviglia GP. Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II). Minerva Med 2022;113:106-8. [PMID: 35313441 DOI: 10.23736/S0026-4806.21.07952-0] [Reference Citation Analysis]
|
| 251 |
Dawuti W, Zheng X, Liu H, Zhao H, Dou J, Sun L, Chu J, Lin R, Lü G. Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma. Photodiagnosis Photodyn Ther 2022;:102811. [PMID: 35304310 DOI: 10.1016/j.pdpdt.2022.102811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 252 |
Pan J, Tao Y, Chi X, Yang L, Zhao Y, Chen F. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis. Eur Radiol 2022. [PMID: 35267090 DOI: 10.1007/s00330-022-08665-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 253 |
Novick D, Rajan N, Wei A, Cheng R, Szende A, Baik R, Colman S. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan. Value Health Reg Issues 2022;30:76-82. [PMID: 35278836 DOI: 10.1016/j.vhri.2022.01.001] [Reference Citation Analysis]
|
| 254 |
He Y, Hu B, Zhu C, Xu W, Ge Y, Hao X, Dong B, Chen X, Dong Q, Zhou X. A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma. Front Oncol 2022;12:745258. [DOI: 10.3389/fonc.2022.745258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 255 |
Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 256 |
Yao J, Hua X, Shi J, Hu X, Lui K, He K, Mai J, Lan T, Lu M. LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA. FASEB J 2022;36:e22238. [PMID: 35224785 DOI: 10.1096/fj.202101564R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 257 |
Xu T, Ren L, Liao M, Zhao B, Wei R, Zhou Z, He Y, Zhang H, Chen D, Chen H, Liao W. Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma. JHC 2022;Volume 9:189-201. [DOI: 10.2147/jhc.s356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 258 |
Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.03.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 259 |
Shi Z, Zheng H, Han M, Hu J, Hu Y, Li X, Zhu W, He X, Deng H, Long Q, Huang A. Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.003] [Reference Citation Analysis]
|
| 260 |
Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022;42:492-506. [PMID: 34982503 DOI: 10.1111/liv.15152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 261 |
Park Y, Han Y, Kim D, Cho S, Kim W, Hwang H, Lee HW, Han DH, Kim KS, Yun M, Lee M. Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells. Cancers 2022;14:1205. [DOI: 10.3390/cancers14051205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 262 |
Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 263 |
Mawatari S, Kumagai K, Oda K, Tabu K, Ijuin S, Fujisaki K, Tashima S, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Taniyama O, Toyodome A, Sakae H, Kure T, Sakurai K, Moriuchi A, Kanmura S, Ido A. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus. PLoS One 2022;17:e0262267. [PMID: 35020772 DOI: 10.1371/journal.pone.0262267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 264 |
Chen Y, Zhang J, Liu J, Wang J, Shi C, Lu L, Cheng X, Niu G, Zhang S, Cui D. The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients. Journal of Immunology Research 2022;2022:1-7. [DOI: 10.1155/2022/1817694] [Reference Citation Analysis]
|
| 265 |
Qiong L, Jie Z, Zhong Z, Wen S, Jun Z, Liping L, Jinkui C. Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI. BMJ Open 2022;12:e058461. [PMID: 35177466 DOI: 10.1136/bmjopen-2021-058461] [Reference Citation Analysis]
|
| 266 |
Ratnasari N, Lestari P, Renovaldi D, Raditya Ningsih J, Qoriansas N, Wardana T, Hakim S, Signa Aini Gumilas N, Indrarti F, Triwikatmani C, Bayupurnama P, Setyo Heriyanto D, Astuti I, Mubarika Harjana S. Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients. PLoS One 2022;17:e0263298. [PMID: 35157721 DOI: 10.1371/journal.pone.0263298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 267 |
Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, Kanatsiz E, Kiyak M, Ozdil K, Doganay HL. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. World J Gastroenterol 2022; 28(6): 665-674 [DOI: 10.3748/wjg.v28.i6.665] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 268 |
Verde F, Ponsiglione A. Role of perfusion features in contrast-enhanced ultrasound differential diagnosis of hepatocellular adenoma and carcinoma: Far beyond the gray-scale ultrasound. J Clin Ultrasound 2022;50:222-3. [PMID: 35147999 DOI: 10.1002/jcu.23140] [Reference Citation Analysis]
|
| 269 |
Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep 2022. [PMID: 35142988 DOI: 10.1007/s11894-022-00835-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Li Y, Xu Z, An C, Chen H, Li X. Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization. JPM 2022;12:248. [DOI: 10.3390/jpm12020248] [Reference Citation Analysis]
|
| 271 |
Bae JS, Lee DH, Lee SM, Suh KS, Lee KW, Yi NJ, Lee KB, Kim H, Han JK. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35138137 DOI: 10.2214/AJR.21.27186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 272 |
Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. Transl Cancer Res 2021;10:3979-92. [PMID: 35116696 DOI: 10.21037/tcr-21-741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 273 |
Xie Q, Liu H, Guo Z, Wu Y, He G, Cai L, Pan M, Fu S. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Front Mol Biosci 2022;8:810251. [DOI: 10.3389/fmolb.2021.810251] [Reference Citation Analysis]
|
| 274 |
Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther 2022;55:350-9. [PMID: 34738664 DOI: 10.1111/apt.16685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 275 |
Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol 2022;57:90-8. [PMID: 35031857 DOI: 10.1007/s00535-021-01837-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 276 |
Wang X, Sun Y, Zhou X, Shen Z, Zhang H, Xing J, Zhou Y. Histogram peritumoral enhanced features on MRI arterial phase with extracellular contrast agent can improve prediction of microvascular invasion of hepatocellular carcinoma. Quant Imaging Med Surg 2022;12:1372-84. [PMID: 35111631 DOI: 10.21037/qims-21-499] [Reference Citation Analysis]
|
| 277 |
Jiang H, Song B, Qin Y, Wei Y, Konanur M, Wu Y, Zaki IH, McInnes MDF, Lafata KJ, Bashir MR. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. J Magn Reson Imaging 2022;55:493-506. [PMID: 34236120 DOI: 10.1002/jmri.27824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 278 |
Koh JH, Tan DJH, Ong Y, Lim WH, Ng CH, Tay PWL, Yong JN, Muthiah MD, Tan EX, Pang NQ, Kim BK, Syn N, Kow A, Goh BKP, Huang DQ. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022;11:78-93. [PMID: 35284509 DOI: 10.21037/hbsn-21-350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 279 |
Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Chen C, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Chang TS, Huang J, Yang C, Hu J, Lin C, Chen C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Mo L, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Liu C, Dai C, Chuang W, Lin H, Kao J, Yu M. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.012] [Reference Citation Analysis]
|
| 280 |
Mao Y, Wang J, Zhu Y, Chen J, Mao L, Kong W, Qiu Y, Wu X, Guan Y, He J. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2022;11:13-24. [PMID: 35284527 DOI: 10.21037/hbsn-19-870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 281 |
Hussain HK. Hepatobiliary-Phase Hypointense Nodules without Arterial Phase Hyperenhancement: Time to Act. Acad Radiol 2022;29:211-2. [PMID: 34922829 DOI: 10.1016/j.acra.2021.11.018] [Reference Citation Analysis]
|
| 282 |
Lee MH, Ahn SH, Chan HLY, Choudhry A, Alvani Gani R, Mohamed R, Ong JP, Shukla A, Tan CK, Tanwandee T, Thuy PTT, Neo BL, Tsang V, Youn J, Singh S. Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. J Viral Hepat 2022;29:156-70. [PMID: 34817896 DOI: 10.1111/jvh.13636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 283 |
Bansal S, Lu F, Frehlich L, Wong JK, Burak KW, Wilson SR. A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS. Abdom Radiol (NY) 2022;47:618-29. [PMID: 34800161 DOI: 10.1007/s00261-021-03331-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 284 |
Wu CH, Kao JH. Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria". Hepatol Int 2022. [PMID: 35088387 DOI: 10.1007/s12072-021-10272-w] [Reference Citation Analysis]
|
| 285 |
Duan L, Zhang BH, Liao JX, Zheng XH. Iodized oil CT-guided radiofrequency ablation for hepatocellular carcinoma within Milan criteria. Hepatol Int 2022. [PMID: 35088388 DOI: 10.1007/s12072-021-10274-8] [Reference Citation Analysis]
|
| 286 |
Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e28545. [PMID: 35089192 DOI: 10.1097/MD.0000000000028545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 287 |
Kim YY, Min JH, Hwang JA, Jeong WK, Sinn DH, Lim HK. Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging. Ultrasonography 2022. [PMID: 35439873 DOI: 10.14366/usg.21198] [Reference Citation Analysis]
|
| 288 |
Abdelrahim M, Victor D, Esmail A, Kodali S, Graviss EA, Nguyen DT, Moore LW, Saharia A, McMillan R, Fong JN, Uosef A, Elshawwaf M, Heyne K, Ghobrial RM. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. Cancers (Basel) 2022;14:650. [PMID: 35158918 DOI: 10.3390/cancers14030650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 289 |
Chen Y, Yang Y, Li S, Lin M, Xie X, Shi H, Jiang Y, Zheng S, Shao H, Yang N, Lu M. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients. Front Public Health 2022;9:784718. [DOI: 10.3389/fpubh.2021.784718] [Reference Citation Analysis]
|
| 290 |
Wu MS, Zhong JH, Chen K, Luo CP, Zhang J, Zhou YJ, Ma Y, Xiang BD. Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence. J Clin Transl Res 2022;8:71-9. [PMID: 35224238] [Reference Citation Analysis]
|
| 291 |
Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 292 |
Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 293 |
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 294 |
Duc VT, Chien PC, Huyen LDM, Chau TLM, Chanh NDT, Soan DTM, Huyen HC, Thanh HM, Hy LNG, Nam NH, Uyen MTT, Nhi LHH, Minh LHN. Deep Learning Model With Convolutional Neural Network for Detecting and Segmenting Hepatocellular Carcinoma in CT: A Preliminary Study. Cureus 2022. [DOI: 10.7759/cureus.21347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 295 |
Zheng Y, Xu M, Zeng D, Tong H, Shi Y, Feng Y, Zhang X. In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma. Diagn Pathol 2022;17:11. [PMID: 35034659 DOI: 10.1186/s13000-022-01194-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 296 |
Shiha G, Mikhail NNH, Soliman R, Hassan A, Eslam M. Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study. Hepatol Int 2022. [PMID: 35034266 DOI: 10.1007/s12072-021-10284-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 297 |
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 298 |
Wang JH, Chen YY, Kee KM, Wang CC, Tsai MC, Kuo YH, Hung CH, Li WF, Lai HL, Chen YH. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers (Basel) 2022;14:343. [PMID: 35053508 DOI: 10.3390/cancers14020343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 299 |
Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 300 |
Nie G, Peng D, Li B, Lu J, Xiong X. Diagnostic Accuracy of Circular RNAs in Different Types of Samples for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:794105. [PMID: 34992634 DOI: 10.3389/fgene.2021.794105] [Reference Citation Analysis]
|
| 301 |
Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 302 |
Dong Y, Zuo D, Qiu YJ, Cao JY, Wang HZ, Yu LY, Wang WP. Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomic features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study. Clin Hemorheol Microcirc 2022. [PMID: 35001883 DOI: 10.3233/CH-211363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 303 |
Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, Chang ML, Lin CL, Yeh CT. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int 2022. [PMID: 34982369 DOI: 10.1007/s12072-021-10283-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 304 |
Kim DH, Choi SH, Lee JS, Choi JI. Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis. Abdom Radiol (NY) 2022;47:123-32. [PMID: 34633497 DOI: 10.1007/s00261-021-03297-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 305 |
Coombs PR, Warsa M, Hailu T, Agedew E, Tsegaye B. Establishing an Ultrasound Screening Protocol for Chronic Liver Disease with a Handheld Device: A Pilot Project in Southern Ethiopia. Ultrasound in Medicine & Biology 2022. [DOI: 10.1016/j.ultrasmedbio.2021.12.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 306 |
Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int 2022;42:59-68. [PMID: 34687130 DOI: 10.1111/liv.15085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 307 |
Attia MS, Mohamed AA, El-saady MM, Abou-omar MN, Afify HG, Amin TA, Hosny AH, Youssef AO, Mohy-eldin MS. A new method for early diagnosis of liver cancer using a biosensor embedded in an alginate polymer thin film. J Mater Chem C 2022;10:6464-72. [DOI: 10.1039/d2tc00209d] [Reference Citation Analysis]
|
| 308 |
Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2022;20:183-93. [PMID: 32927050 DOI: 10.1016/j.cgh.2020.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 309 |
Sandhu N, Rossi S. Diagnosis and Evaluation of Hepatocellular Carcinoma. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_4] [Reference Citation Analysis]
|
| 310 |
Guan R, Sun B, Wang Z, Zhou C, Yang Z, Gan W, Huang J, Liu G, Zhou J, Fan J, Yi Y, Qiu S. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.01.008] [Reference Citation Analysis]
|
| 311 |
Mojtahed A, Núñez L, Connell J, Fichera A, Nicholls R, Barone A, Marieiro M, Puddu A, Arya Z, Ferreira C, Ridgway G, Kelly M, Lamb HJ, Caseiro-Alves F, Brady JM, Banerjee R. Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. Abdom Radiol (NY) 2022;47:143-51. [PMID: 34605963 DOI: 10.1007/s00261-021-03262-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 312 |
Jearth V, Patil PS, Mehta S, Sundaram S, Seth V, Goel M, Patkar S, Bal M, Rao V. Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken. J Clin Exp Hepatol 2022;12:841-52. [PMID: 35677513 DOI: 10.1016/j.jceh.2021.11.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 313 |
Zhao H, Lu B. Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma. CMAR 2022;Volume 14:249-55. [DOI: 10.2147/cmar.s344711] [Reference Citation Analysis]
|
| 314 |
Issamatov B, Zholdybay Z, Tajibaev T, Serikuly E, Baimakhanov B, Medeubekov U, Sagatov I. Feature analysis of computed tomographic signs of hepatocellular carcinoma in multiphase studies. NAMJ 2022. [DOI: 10.56936//18290825-2022.16.1-23] [Reference Citation Analysis]
|
| 315 |
Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2022;20:44-56.e2. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 316 |
Pagano D, Mamone G, Calamia S, Gruttadauria S. Surgical Management of Hepatocellular Carcinoma. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_7] [Reference Citation Analysis]
|
| 317 |
Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
|
| 318 |
Delvecchio A, Inchingolo R, Laforgia R, Ratti F, Gelli M, Anelli MF, Laurent A, Vitali G, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, di Benedetto F, de'Angelis N, Briceño J, Rampoldi A, Adam R, Cherqui D, Aldrighetti LA, Memeo R. Liver resection vs radiofrequency ablation in single hepatocellular carcinoma of posterosuperior segments in elderly patients. World J Gastrointest Surg 2021;13:1696-707. [PMID: 35070074 DOI: 10.4240/wjgs.v13.i12.1696] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 319 |
Zhao C, Dai H, Shao J, He Q, Su W, Wang P, Tang Q, Zeng J, Xu S, Zhao J, Xiang S. Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:680691. [PMID: 34950573 DOI: 10.3389/fonc.2021.680691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 320 |
Qu M, Jia Z, Sun L, Wang H. Diagnostic accuracy of three-dimensional contrast-enhanced ultrasound for focal liver lesions: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28147. [PMID: 34941062 DOI: 10.1097/MD.0000000000028147] [Reference Citation Analysis]
|
| 321 |
Wu T, Ke Y, Tang H, Liao C, Li J, Wang L. Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma. Mol Ther Oncolytics 2021;23:420-31. [PMID: 34853813 DOI: 10.1016/j.omto.2021.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 322 |
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. [PMID: 34914889 DOI: 10.1016/S1470-2045(21)00604-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 137] [Article Influence: 52.0] [Reference Citation Analysis]
|
| 323 |
Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 324 |
Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma 2021;8:1565-77. [PMID: 34909425 DOI: 10.2147/JHC.S335879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 325 |
Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 326 |
Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 327 |
Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. J Cell Biochem 2021. [PMID: 34897788 DOI: 10.1002/jcb.30190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 328 |
Okubo H, Ando H, Nakadera E, Ikejima K, Shiina S, Nagahara A. Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. Nutrients 2021;13:4428. [PMID: 34959980 DOI: 10.3390/nu13124428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 329 |
Jiang H, Yuan F, Zhao Z, Xue T, Ge N, Ren Z, Zhang L. Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma. Int J Gen Med 2021;14:9145-52. [PMID: 34880653 DOI: 10.2147/IJGM.S334378] [Reference Citation Analysis]
|
| 330 |
Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 331 |
Elpek GO. Orosomucoid in liver diseases. World J Gastroenterol 2021; 27(45): 7739-7747 [PMID: 34963738 DOI: 10.3748/wjg.v27.i45.7739] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 332 |
He L, Wang S, Ma X. The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. Biomed Res Int 2021;2021:7377299. [PMID: 34869770 DOI: 10.1155/2021/7377299] [Reference Citation Analysis]
|
| 333 |
Dong Y, Koch JBH, Löwe AL, Christen M, Wang WP, Jung EM, Mohaupt MG, Dietrich CF. VueBox® for quantitative analysis of contrast-enhanced ultrasound in liver tumors. Clin Hemorheol Microcirc 2021. [PMID: 34897079 DOI: 10.3233/CH-211261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 334 |
Wang Z, Yu XL, Zhang J, Cheng ZG, Han ZY, Liu FY, Dou JP, Kong Y, Dong XJ, Zhao QX, Yu J, Liang P, Tang WZ. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol 2021;281:114539. [PMID: 34428522 DOI: 10.1016/j.jep.2021.114539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 335 |
Kim JG, Cho SK, Hyun D, Shin SW, Park KB, Park HS, Choo SW, Do YS, Woo SY, Baek SY. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study. Abdom Radiol (NY) 2021;46:5735-45. [PMID: 34581928 DOI: 10.1007/s00261-021-03291-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 336 |
Zhou W, Zhang Y, Zhang S, Yang Z. Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma. Bioengineered 2021;12:2750-62. [PMID: 34130591 DOI: 10.1080/21655979.2021.1939636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 337 |
Morris KE, Muir AJ. Care After Cure: Long-term Follow-up in Hepatitis C. Curr Hepatology Rep 2021;20:183-190. [DOI: 10.1007/s11901-021-00579-5] [Reference Citation Analysis]
|
| 338 |
Kang N, Chung JW, Jang ES, Jeong SH, Kim JW. Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Dig Dis Sci 2021;66:4536-44. [PMID: 33630218 DOI: 10.1007/s10620-020-06762-w] [Reference Citation Analysis]
|
| 339 |
Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 340 |
Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021;13:1568-83. [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 341 |
An J. [Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis]. Korean J Gastroenterol 2021;78:255-60. [PMID: 34824183 DOI: 10.4166/kjg.2021.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 342 |
Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 343 |
Zhang F, Zheng L, Li D, Yang H. To explore the curative effect of CT-guided Iodine-125 radioactive seed implantation in the treatment of stage Ⅳprimary hepatocellular carcinoma. J Interv Med 2021;4:82-6. [PMID: 34805953 DOI: 10.1016/j.jimed.2021.02.009] [Reference Citation Analysis]
|
| 344 |
Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 345 |
Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 346 |
Shin SW, Cho SK, Hyun D, Park KB, Park HS, Do YS. Guidewire-catheter induced hydrodissection to assist radiofrequency ablation for subcapsular hepatocellular carcinoma with iodized oil retention in patients with failed artificial ascites due to perihepatic adhesion. Diagn Interv Radiol 2021;27:746-53. [PMID: 34792029 DOI: 10.5152/dir.2021.21056] [Reference Citation Analysis]
|
| 347 |
Yang Y, Zhou Y, Zhou C, Ma X. Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00927-6. [PMID: 34862094 DOI: 10.1016/j.ejso.2021.11.120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 348 |
Wei J, Liu Y, Zhao C. Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:719973. [PMID: 34790567 DOI: 10.3389/fonc.2021.719973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 349 |
Du Y, Ma X, Wang D, Wang Y, Zhang T, Bai L, Liu Y, Chen S. Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:2361-76. [PMID: 34790398 DOI: 10.21037/jgo-21-468] [Reference Citation Analysis]
|
| 350 |
Kаrmаzаnovsky GG, Volobueva AA. Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoxetic Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma. Vestn rentgenol radiol 2021;102:284-295. [DOI: 10.20862/0042-4676-2021-102-5-284-295] [Reference Citation Analysis]
|
| 351 |
Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF, Yu ML. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Med 2021. [PMID: 34786871 DOI: 10.1002/cam4.4430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 352 |
Chen LC, Lin HY, Lee MS, Chiou WY, Huang LW, Chew CH, Hsu FC, Hung SK. Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. Tzu Chi Med J 2021;33:380-7. [PMID: 34760635 DOI: 10.4103/tcmj.tcmj_247_20] [Reference Citation Analysis]
|
| 353 |
Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 354 |
Li YC, Chen PH, Yeh JH, Hsiao P, Lo GH, Tan T, Cheng PN, Lin HY, Chen YS, Hsieh KC, Hsieh PM, Lin CW. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:418. [PMID: 34749663 DOI: 10.1186/s12876-021-01995-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 355 |
Deng M, Li S, Guo R. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. The American Surgeon 2021. [DOI: 10.1177/00031348211054532] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 356 |
Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 357 |
Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 358 |
Cachay ER, Hadigan C, Mathews WC. Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. AIDS 2021;35:2211-3. [PMID: 34602589 DOI: 10.1097/QAD.0000000000003022] [Reference Citation Analysis]
|
| 359 |
Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 360 |
Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 361 |
Kokudo T, Hasegawa K. Evaluating the liver function of patients with hepatocellular carcinoma. Hepatol Res 2021;51:1095-6. [PMID: 34724293 DOI: 10.1111/hepr.13705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 362 |
Shiha G, Soliman R, Mikhail N, Hassan A, Eslam M. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk‐based surveillance using pre‐ and post‐treatment general evaluation score. Liver International 2021;41:2768-2776. [DOI: 10.1111/liv.14995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 363 |
Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
|
| 364 |
Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev 2022;9:nwab192. [PMID: 35382356 DOI: 10.1093/nsr/nwab192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 365 |
Liu KC, Lv WF, Lu D, Hou CL, Xie J, Lu YH, Cao QS, Tan YL, Zhang YZ, Liu J. Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma. Cancer Manag Res 2021;13:7973-80. [PMID: 34703317 DOI: 10.2147/CMAR.S332571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 366 |
Liu Y, Yang Y, Jiang L, Xu H, Wei J. High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma. J Oncol 2021;2021:5680968. [PMID: 34697542 DOI: 10.1155/2021/5680968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 367 |
Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Aiyama T, Sakamoto Y, Kamachi H, Taketomi A. Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1245-1257 [PMID: 34754392 DOI: 10.4240/wjgs.v13.i10.1245] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 368 |
Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 369 |
Nie G, Peng D, Li B, Lu J, Cai Y, Xiong X, Cheng N. Diagnostic Accuracy of Serum/Plasma Circular RNAs and the Combination of Circular RNAs and α-Fetoprotein for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:722208. [PMID: 34659344 DOI: 10.3389/fgene.2021.722208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 370 |
Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 371 |
Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 372 |
Wang M, Xiong Z. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Int J Gen Med 2021;14:6343-58. [PMID: 34629898 DOI: 10.2147/IJGM.S333390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 373 |
Zakir U, Siddiqui NN, Naqvi FU, Khan R. Aberrant STAT1 methylation as a non-invasive biomarker in blood of HCV induced hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 34657877 DOI: 10.3233/CBM-210216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 374 |
Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 375 |
Gong XQ, Tao YY, Wu YK, Liu N, Yu X, Wang R, Zheng J, Liu N, Huang XH, Li JD, Yang G, Wei XQ, Yang L, Zhang XM. Progress of MRI Radiomics in Hepatocellular Carcinoma. Front Oncol 2021;11:698373. [PMID: 34616673 DOI: 10.3389/fonc.2021.698373] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 376 |
Chang YS, Lee YT, Yen JC, Chang YC, Lin LL, Chan WL, Chang WC, Lin SY, Chang JG. Long Noncoding RNA NTT Context-Dependently Regulates MYB by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:592045. [PMID: 34616668 DOI: 10.3389/fonc.2021.592045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 377 |
Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 378 |
Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 379 |
Yu SCH. Blood Flow Diversion Within Hepatocellular Carcinoma (HCC) after Selective Occlusion of Feeding Arteries (SOFA) and Feasibility of Utilizing the SOFA Technique in Transarterial Chemoembolization (SOFA-TACE). Cardiovasc Intervent Radiol 2021. [PMID: 34604919 DOI: 10.1007/s00270-021-02973-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 380 |
Zhang A, Xiao Z, Liu Q, Li P, Xu F, Liu J, Tao H, Feng L, Song S, Liu Z, Huang G. CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2100748. [PMID: 34137207 DOI: 10.1002/adhm.202100748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 381 |
Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021;28:1431-42. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 382 |
Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2021;28:1464-76. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 383 |
Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat 2021;28:1373-80. [PMID: 34218498 DOI: 10.1111/jvh.13569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 384 |
Kim TH, Kim NH, Kim JD, Kim YN, Kim YJ, Kim EJ, Yoo KD, Ryu CH, Song HH, Kim H. Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial. J Liver Cancer 2021;21:146-154. [DOI: 10.17998/jlc.2021.05.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 385 |
Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 386 |
Ma C, Ma Y, Lu S, Li D, Wang Y, Xu Y, Zhang T, Du Y, Wang L. Clinical Study on Effect of Solution Focused Approach on the Complications, Pain, Sleep, and Quality of Life in Patients with Hepatocellular Carcinoma Undergoing TACE. Evid Based Complement Alternat Med 2021;2021:5068228. [PMID: 34567212 DOI: 10.1155/2021/5068228] [Reference Citation Analysis]
|
| 387 |
Kim DH, Kim B, Youn SY, Kim H, Choi JI. Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1763. [PMID: 34679461 DOI: 10.3390/diagnostics11101763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 388 |
Zhou N, Li S, Wu D, Zhang F, Tang F, Li Y. The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis. DNA Cell Biol 2021;40:1278-89. [PMID: 34558987 DOI: 10.1089/dna.2021.0235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 389 |
Ye D, Qu J, Wang J, Li G, Sun B, Xu Q. A New Clinical Nomogram From the TCGA Database to Predict the Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:698980. [PMID: 34552865 DOI: 10.3389/fonc.2021.698980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 390 |
Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 391 |
Wang X, Yuan Y, Wang J, Liu Z, Chen M, Zhou Q, Zhou Z. Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma. J Cancer 2021;12:6231-41. [PMID: 34539896 DOI: 10.7150/jca.55806] [Reference Citation Analysis]
|
| 392 |
Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 393 |
Cannella R, Vernuccio F, Antonucci M, Gagliano DS, Matteini F, Midiri M, Brancatelli G. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations? Eur Radiol 2021. [PMID: 34545444 DOI: 10.1007/s00330-021-08267-0] [Reference Citation Analysis]
|
| 394 |
Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 395 |
Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 396 |
Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 397 |
Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 398 |
You Z, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, Peng X. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. J Cell Mol Med 2021;25:9168-82. [PMID: 34510715 DOI: 10.1111/jcmm.16792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 399 |
Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Kim KW, Choi JI. Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1665. [PMID: 34574006 DOI: 10.3390/diagnostics11091665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 400 |
Chen YY, Chen CL, Lin CC, Wang CC, Liu YW, Li WF, Chen YH. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers (Basel) 2021;13:4584. [PMID: 34572811 DOI: 10.3390/cancers13184584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 401 |
Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 402 |
Lu Y, Pan J, Zhu X, Zhang S, Liu C, Sun J, Li Y, Chen S, Huang J, Cao C, Wang Y, Li Y, Liu T. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma. BMC Pharmacol Toxicol 2021;22:48. [PMID: 34488896 DOI: 10.1186/s40360-021-00515-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 403 |
Agnello F, Rabiolo L, Midiri F, Lo Re G, Grassedonio E, La Grutta L, Buscemi S, Agrusa A, Galia M. Focal hepatic intrinsically hyperattenuating lesions at unenhanced CT: Not always calcifications. Clin Imaging 2021;80:304-14. [PMID: 34482241 DOI: 10.1016/j.clinimag.2021.08.020] [Reference Citation Analysis]
|
| 404 |
Ren S, Qi Q, Liu S, Duan S, Mao B, Chang Z, Zhang Y, Wang S, Zhang L. Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: A multicenter study. Eur J Radiol 2021;143:109891. [PMID: 34481117 DOI: 10.1016/j.ejrad.2021.109891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 405 |
Nishikawa H, Shiraki M, Hiramatsu A, Hara N, Moriya K, Hino K, Koike K. Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. Hepatol Res 2021;51:957-67. [PMID: 34057800 DOI: 10.1111/hepr.13679] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 406 |
Nguyen YTH, Diep YN, Huynh YK, Pham TT, Nguyen T, Tran DTN, Tran LTN, Trinh CTH, Cao NM, Nguyen BT. Distribution of Hepatitis B Virus Genotypes, Subgenotypes, and Prevalence of Hepatitis B Virus Mutations in Untreated Patients With Chronic Hepatitis B From Mekong Delta. Infect Dis Clin Pract 2021;29:e301-e304. [DOI: 10.1097/ipc.0000000000000990] [Reference Citation Analysis]
|
| 407 |
Ding WB, Wang MC, Yu J, Huang G, Sun DP, Liu L, Zhang JN, Yang Y, Liu H, Zhou WP, Yang F, Yuan SX. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3. Hepatology 2021;74:1480-95. [PMID: 33825218 DOI: 10.1002/hep.31850] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 408 |
Lim MS, Goh GB, Chang JP, Low JK, Shelat VG, Huey TC, Dan YY, Kow A, Shridhar I, Tan PS, Junnarkar SP, Tan CK. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open 2021;5:1015-8. [PMID: 34584969 DOI: 10.1002/jgh3.12624] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 409 |
Kim HI, Lim J, Shim JH. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2021. [PMID: 34459972 DOI: 10.1007/s00432-021-03727-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 410 |
Zhao T, Guo BJ, Xiao CL, Chen JJ, Lü C, Fang FF, Li B. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med 2021;19:418-27. [PMID: 34454893 DOI: 10.1016/j.joim.2021.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 411 |
Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021;13:949-68. [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 412 |
Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
|
| 413 |
Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 414 |
Chang WC, Hsu HH, Chiu SH, Huang WY, Lo CH, Lin HH, Huang PC, Shih YL, Wan YL. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads. J Hepatocell Carcinoma 2021;8:937-49. [PMID: 34422707 DOI: 10.2147/JHC.S319920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 415 |
Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 416 |
Luo L, Li Q, Su Z, Li L, Cai B, Peng Y, Bai Y, Liu F. Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:700711. [PMID: 34422654 DOI: 10.3389/fonc.2021.700711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 417 |
Li B, Zhao Y, Cai W, Ming A, Li H. Validation and update of a multivariable prediction model for the identification and management of patients at risk for hepatocellular carcinoma. Clin Proteomics 2021;18:21. [PMID: 34412596 DOI: 10.1186/s12014-021-09326-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 418 |
Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;15:1083-92. [PMID: 34402025 DOI: 10.1007/s12072-021-10234-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 419 |
Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 420 |
Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 421 |
Yang CJ, Wang CK, Fang YD, Wang JY, Su FC, Tsai HM, Lin YJ, Tsai HW, Yeh LR. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. PLoS One 2021;16:e0255605. [PMID: 34375365 DOI: 10.1371/journal.pone.0255605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 422 |
Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 423 |
Lin ZZ, Bo N, Fan YC, Wu YT, Yao HL, Chen S, Yu HF, Jiang LH. Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via Μu-opioid receptor. J Pharm Pharmacol 2021:rgab104. [PMID: 34355768 DOI: 10.1093/jpp/rgab104] [Reference Citation Analysis]
|
| 424 |
Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 425 |
Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
|
| 426 |
Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 427 |
Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 428 |
Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. Am J Gastroenterol 2021;116:1698-708. [PMID: 33900211 DOI: 10.14309/ajg.0000000000001256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 429 |
Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 430 |
Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 431 |
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 2021;51:880-9. [PMID: 33837620 DOI: 10.1111/hepr.13644] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 432 |
Masch WR, Kampalath R, Parikh N, Shampain KA, Aslam A, Chernyak V. Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3625-33. [PMID: 33950406 DOI: 10.1007/s00261-021-03100-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 433 |
Liu L, Liang X, Xu X, Zhang X, Wen J, Chen K, Su X, Teng Z, Lu G, Xu J. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. Acta Biomater 2021;130:374-84. [PMID: 34082098 DOI: 10.1016/j.actbio.2021.05.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 434 |
Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 435 |
Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer 2021;10:629-40. [PMID: 34950185 DOI: 10.1159/000517393] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 436 |
Khan AA, Hadi YB, Thompson JM, Kupec JT. Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. BMJ Open Gastroenterol 2020;7:e000394. [PMID: 32398242 DOI: 10.1136/bmjgast-2020-000394] [Reference Citation Analysis]
|
| 437 |
Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver? Ultrasound Med Biol 2021;47:2930-5. [PMID: 34266681 DOI: 10.1016/j.ultrasmedbio.2021.05.004] [Reference Citation Analysis]
|
| 438 |
Wang X, Lei Y, Huan H, Chen S, Ma K, Feng K, Lau WY, Xia F. Bisegmentectomy 7-8 for Small-for-Size Remanant Liver for Cirrhotic Patients Under Right Hemi-hepatectomy With Hepatocellular Carcinoma: A Case-Matched Comparative Study. Front Surg 2021;8:675666. [PMID: 34336916 DOI: 10.3389/fsurg.2021.675666] [Reference Citation Analysis]
|
| 439 |
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 440 |
Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 441 |
Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 442 |
Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 443 |
Shi Q, Lu Y, Huang S, Zhou C, Yang C, Liu J, Ma J, Xiong B. Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo. Drug Deliv 2020;27:1301-7. [PMID: 32924634 DOI: 10.1080/10717544.2020.1818881] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 444 |
Hui Y, Zeng H, Feng Y, Qin W, Chen P, Huang L, Zhong W, Lin L, Lv H, Qin X. Regulatory Role of SFN Gene in Hepatocellular Carcinoma and Its Mechanism. Biotechnol Bioproc E 2021;26:375-83. [DOI: 10.1007/s12257-020-0292-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 445 |
Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
|
| 446 |
Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 447 |
Zhou Y, Ouyang J, Wang Z, Chen X, Zhu R, Li Q, Zhou J. A novel internal cold circulation radiofrequency-assisted device for liver transection. Int J Hyperthermia 2021;38:308-15. [PMID: 33627010 DOI: 10.1080/02656736.2021.1889046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 448 |
Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
|
| 449 |
Ding R, Chen T, Zhang Y, Chen X, Zhuang L, Yang Z. HMGCS2 in metabolic pathways was associated with overall survival in hepatocellular carcinoma: A LASSO-derived study. Sci Prog 2021;104:368504211031749. [PMID: 34260294 DOI: 10.1177/00368504211031749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 450 |
Kamalapirat T, Yingcharoen K, Ungtrakul T, Soonklang K, Dechma J, Chunnuan P, Kusuman P, Pothijaroen C, Tawpa J, Cheirsilpa K, Auewarakul C. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B. J Viral Hepat 2021;28:1034-41. [PMID: 33880807 DOI: 10.1111/jvh.13517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 451 |
Chaikajornwat J, Tanasoontrarat W, Phathong C, Pinjaroen N, Chaiteerakij R. Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center. Liver Research 2021. [DOI: 10.1016/j.livres.2021.07.001] [Reference Citation Analysis]
|
| 452 |
Öcal O, Rössler D, Ricke J, Seidensticker M. Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. Dig Dis 2022;40:458-67. [PMID: 34348282 DOI: 10.1159/000518101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 453 |
Li Q, Zhu H. Donafenib treatment for hepatocellular carcinoma: A case report. Medicine (Baltimore) 2021;100:e26373. [PMID: 34160411 DOI: 10.1097/MD.0000000000026373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 454 |
Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS. Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. J Hepatocell Carcinoma 2021;8:657-70. [PMID: 34235104 DOI: 10.2147/JHC.S316223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Wang H, Lee JC, Cao K, Tang HW, Wang S, Zhang ZY, Wu W, Yan K, Yang W. What is the difference in ablation zone of multi-bipolar radiofrequency ablation between liver cirrhosis and normal liver background? - a prospective clinical study. Int J Hyperthermia 2020;37:1248-59. [PMID: 33164634 DOI: 10.1080/02656736.2020.1838627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 456 |
Wang F, Numata K, Nihonmatsu H, Chuma M, Moriya S, Nozaki A, Ogushi K, Fukuda H, Ruan L, Okada M, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. Int J Hyperthermia 2020;37:1149-58. [PMID: 32996799 DOI: 10.1080/02656736.2020.1825837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 457 |
Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Addo BP. Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana. PLoS One 2021;16:e0253759. [PMID: 34166471 DOI: 10.1371/journal.pone.0253759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 458 |
Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 459 |
Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 460 |
Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 461 |
Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 462 |
Wan Y, Zheng Z, Liu R, Zhu Z, Zhou H, Zhang X, Boumaraf S. A Multi-Scale and Multi-Level Fusion Approach for Deep Learning-Based Liver Lesion Diagnosis in Magnetic Resonance Images with Visual Explanation. Life (Basel) 2021;11:582. [PMID: 34207262 DOI: 10.3390/life11060582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 463 |
Jeon SK, Joo I, Bae JS, Park SJ, Lee JM. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Eur Radiol 2021. [PMID: 34132875 DOI: 10.1007/s00330-021-08116-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 464 |
Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 465 |
Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Choi JI. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. Cancers (Basel) 2021;13:2975. [PMID: 34198589 DOI: 10.3390/cancers13122975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 466 |
Zhou G, Zeng Y, Luo Y, Guo S, Bao L, Zhang Q. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00579-5. [PMID: 34175168 DOI: 10.1016/j.ejso.2021.06.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 467 |
Costentin CE, Nahon P. HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor? JHEP Rep 2021;3:100320. [PMID: 34308325 DOI: 10.1016/j.jhepr.2021.100320] [Reference Citation Analysis]
|
| 468 |
Kuznetsov OE, Grodno State Medical University, Grodno, Belarus, Tsyrkunov VM, Grodno State Medical University, Grodno, Belarus. VIRUS-ASSOCIATED HEPATOCELLULAR LIVER CANCER. Hepatol and Gastroenterol 2021;5:17-24. [DOI: 10.25298/2616-5546-2021-5-1-17-24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 469 |
Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 470 |
Chon HY, Seo YS, Lee JI, Kim BS, Jang BK, Kim SG, Suk KT, Kim IH, Lee JW, Chon YE, Kim MY, Jeong SW, Lee HA, Yim SY, Um SH, Lee HW, Lee KS, Song JE, Lee CH, Chung WJ, Hwang JS, Yoo JJ, Kim YS, Kim DJ, Lee CH, Yu JH, Ha YJ, Kim MN, Lee JH, Hwang SG, Kang SH, Baik SK, Jang JY, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:885-93. [PMID: 32541238 DOI: 10.1097/MEG.0000000000001794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 471 |
Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 472 |
Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 473 |
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 124] [Cited by in F6Publishing: 125] [Article Influence: 62.0] [Reference Citation Analysis]
|
| 474 |
Wang F, Numata K, Okada M, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Luo W, Ruan L, Nakano M, Otani M, Inayama Y, Maeda S. Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma. Quant Imaging Med Surg 2021;11:2521-40. [PMID: 34079721 DOI: 10.21037/qims-20-685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Wang F, Numata K, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Fukuda H, Okada M, Ruan L, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:2527-39. [PMID: 33388895 DOI: 10.1007/s00261-020-02881-0] [Reference Citation Analysis]
|
| 476 |
Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265-77. [PMID: 33655714 DOI: 10.1111/liv.14849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 477 |
Jung D, Hwang S, Song G. Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. Ann Liver Transplant 2021;1:48-66. [DOI: 10.52604/alt.11.0007] [Reference Citation Analysis]
|
| 478 |
Jung D, Hwang S, Song G. Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. Ann Liver Transplant 2021;1:29-47. [DOI: 10.52604/alt.21.0005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 479 |
Hamada K, Itoh T, Kawaura K, Kuno H, Kamai J, Kobayasi R, Azukisawa S, Kitakata H, Ishisaka T, Igarashi Y, Kodera K, Okuno T, Morita T, Himeno T, Yano H, Higashikawa T, Iritani O, Iwai K, Morimoto S, Matoba M, Okuro M. A Case of Refractory Esophageal Ulcer Caused by Radiotherapy for Hepatocellular Carcinoma. World J Oncol 2021;12:67-72. [PMID: 34046101 DOI: 10.14740/wjon1370] [Reference Citation Analysis]
|
| 480 |
Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 481 |
Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 482 |
Stocker D, Hectors S, Bane O, Vietti-Violi N, Said D, Kennedy P, Cuevas J, Cunha GM, Sirlin CB, Fowler KJ, Lewis S, Taouli B. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. Eur Radiol 2021. [PMID: 34043055 DOI: 10.1007/s00330-021-08068-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 483 |
Chen D, Yan Y, Wang X, Li S, Liu Y, Yu D, He Y, Deng R, Liu Y, Xu M, Luo J, Gao H, Wang S. Chronic alcohol exposure promotes HCC stemness and metastasis through β-catenin/miR-22-3p/TET2 axis. Aging (Albany NY) 2021;13:14433-55. [PMID: 34019487 DOI: 10.18632/aging.203059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 484 |
Hu C, Song Y, Zhang J, Dai L, Tang C, Li M, Liao W, Zhou Y, Xu Y, Zhang YY, Zhou Y. Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy. Front Oncol 2021;11:649682. [PMID: 34094938 DOI: 10.3389/fonc.2021.649682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 485 |
Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 486 |
Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 487 |
Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. J Int Med Res 2020;48:300060520961260. [PMID: 33044114 DOI: 10.1177/0300060520961260] [Reference Citation Analysis]
|
| 488 |
Wang J, Wang J, Wang J, Qian Z, Xu W, Hang X. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. J Int Med Res 2021;49:300060521994406. [PMID: 33596694 DOI: 10.1177/0300060521994406] [Reference Citation Analysis]
|
| 489 |
Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 490 |
Varol Fİ. Pediatric Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1169-75. [PMID: 32856229 DOI: 10.1007/s12029-020-00494-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 491 |
Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
|
| 492 |
Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 493 |
Lee CM, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int 2021;15:676-84. [PMID: 33956288 DOI: 10.1007/s12072-021-10190-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 494 |
Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D; Cochrane Hepato-Biliary Group. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd014798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 495 |
Kiri L, Abdolell M, Costa AF, Keough V, Rowe J, Butt R, Clarke SE. US LI-RADS Visualization Score: Interobserver Variability and Association With Cause of Liver Disease, Sex, and Body Mass Index. Can Assoc Radiol J 2021;:8465371211012104. [PMID: 33938768 DOI: 10.1177/08465371211012104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 496 |
Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 497 |
Feng Z, Zhao H, Guan S, Wang W, Rong P. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis. Liver Int 2021;41:1117-28. [PMID: 33647177 DOI: 10.1111/liv.14850] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 498 |
Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 174] [Cited by in F6Publishing: 164] [Article Influence: 87.0] [Reference Citation Analysis]
|
| 499 |
Rimola J, Forner A. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Liver Int 2021;41:888-90. [PMID: 33861894 DOI: 10.1111/liv.14883] [Reference Citation Analysis]
|
| 500 |
Seo JY, Shin DW, Yu SJ, Jung JH, Han K, Cho IY, Kim SY, Choi KS, Park JH, Park JH, Kawachi I. Disparities in Liver Cancer Surveillance Among People With Disabilities: A National Database Study in Korea. J Clin Gastroenterol 2021;55:439-48. [PMID: 32889960 DOI: 10.1097/MCG.0000000000001405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 501 |
Wei J, Ma L, Liu W, Wang Y, Shen C, Zhao X, Zhao C. Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis. J Ethnopharmacol 2021;276:114174. [PMID: 33932512 DOI: 10.1016/j.jep.2021.114174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 502 |
Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 503 |
Li JL, Ye WT, Yan LF, Liu ZY, Cao XM, Liang CH. Influence of tube voltage, tube current and newer iterative reconstruction algorithms in CT perfusion imaging in rabbit liver VX2 tumors. Diagn Interv Radiol 2020;26:264-70. [PMID: 32490833 DOI: 10.5152/dir.2019.19147] [Reference Citation Analysis]
|
| 504 |
Lin CC, Lui KW, Chen WT, Hsieh YC, Cheng YT, Teng W, Lin SM. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33895858 DOI: 10.1007/s00330-021-07729-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 505 |
Hwang JA, Min JH, Kang TW, Jeong WK, Kim YK, Ko SE, Choi SY. Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. Eur Radiol 2021. [PMID: 33856517 DOI: 10.1007/s00330-021-07897-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 506 |
Ghiuchici AM, Sporea I, Dănilă M, Șirli R, Moga T, Bende F, Popescu A. Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma? J Clin Med 2021;10:1710. [PMID: 33921086 DOI: 10.3390/jcm10081710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 507 |
Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 508 |
Chen J, Xia C, Duan T, Cao L, Jiang H, Liu X, Zhang Z, Ye Z, Wu Z, Gao R, Shi Y, Song B. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021. [PMID: 33856520 DOI: 10.1007/s00330-021-07898-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 509 |
Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 510 |
Yang PW, Chen TT, Zhao WX, Liu GW, Feng XJ, Wang SM, Pan YC, Wang Q, Zhang SH. Scutellaria barbata D.Don and Oldenlandia diffusa (Willd.) Roxb crude extracts inhibit hepatitis-B-virus-associated hepatocellular carcinoma growth through regulating circRNA expression. J Ethnopharmacol 2021;275:114110. [PMID: 33864890 DOI: 10.1016/j.jep.2021.114110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 511 |
Strobel D. Using contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma - what we have and have not achieved. Ultraschall Med 2021;42:120-4. [PMID: 33845488 DOI: 10.1055/a-1347-1388] [Reference Citation Analysis]
|
| 512 |
Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021;21:401. [PMID: 33849479 DOI: 10.1186/s12885-021-08138-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 513 |
Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20201928. [PMID: 33835138 DOI: 10.1042/BSR20201928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 514 |
Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 515 |
Chen Y, Xia Y, Tolat PP, Long L, Jiang Z, Huang Z, Tang Q. Comparison of Conventional Gadoxetate Disodium-Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion. AJR Am J Roentgenol 2021;216:1510-20. [PMID: 33826360 DOI: 10.2214/AJR.20.23255] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 516 |
Yu MQ, An TZ, Li JX, Chang DH, Zhang ZS, Xiao YD. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:1194-202. [PMID: 33819601 DOI: 10.1016/j.jvir.2021.03.540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 517 |
Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 518 |
Su F, Weiss NS, Beste LA, Moon AM, Jin GY, Green P, Berry K, Ioannou GN. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol 2021;74:850-9. [PMID: 33245934 DOI: 10.1016/j.jhep.2020.11.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 519 |
Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, Pryor DI. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol 2021;36:873-84. [PMID: 32632941 DOI: 10.1111/jgh.15175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 520 |
Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-416. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 521 |
Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 522 |
Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatol Res 2021;51:461-71. [PMID: 33217113 DOI: 10.1111/hepr.13595] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 523 |
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223-38. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 395] [Cited by in F6Publishing: 364] [Article Influence: 197.5] [Reference Citation Analysis]
|
| 524 |
Kamarajah SK, Bundred JR, Littler P, Reeves H, Manas DM, White SA. Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. HPB (Oxford) 2021;23:495-505. [PMID: 33309569 DOI: 10.1016/j.hpb.2020.10.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 525 |
Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 526 |
Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 527 |
Yoon SM. External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. J Liver Cancer 2021;21:25-33. [DOI: 10.17998/jlc.21.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 528 |
Deng Z, Jin Z, Qin Y, Wei M, Wang J, Lu T, Zhang L, Zeng J, Bao L, Guo Y, Peng M, Xu B, Wen Z. Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study. World J Surg Oncol 2021;19:95. [PMID: 33785022 DOI: 10.1186/s12957-021-02199-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 529 |
Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 530 |
Collettini F, Reimann C, Brangsch J, Chapiro J, Savic LJ, Onthank DC, Robinson SP, Karst U, Buchholz R, Keller S, Hamm B, Goldberg SN, Makowski MR. Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. Sci Rep 2021;11:6814. [PMID: 33767303 DOI: 10.1038/s41598-021-86417-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 531 |
Park HJ, Seo KI, Kim SJ, Lee SU, Yun BC, Han BH, Shin DH, Choi YI, Moon HH. Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Korean J Gastroenterol 2021;77:115-22. [PMID: 33658474 DOI: 10.4166/kjg.2020.148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 532 |
Sano T, Kawaguchi T, Ide T, Amano K, Kuwahara R, Arinaga-Hino T, Torimura T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. Life (Basel) 2021;11:263. [PMID: 33806752 DOI: 10.3390/life11030263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 533 |
Mishima K, Itano O, Matsuda S, Suzuki S, Onishi A, Tamura M, Inoue M, Abe Y, Yagi H, Hibi T, Kitago M, Shinoda M, Kitagawa Y. Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model. PLoS One 2021;16:e0248352. [PMID: 33750947 DOI: 10.1371/journal.pone.0248352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 534 |
Chen J, Ding Y, Huang F, Lan R, Wang Z, Huang W, Chen R, Wu B, Fu L, Yang Y, Liu J, Hong J, Zhang W, Zhang L. Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. Oncol Lett 2021;21:409. [PMID: 33841570 DOI: 10.3892/ol.2021.12670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 535 |
Kаrmаzаnovsky GG, Shantarevich MY. The review of international clinical guidelines and clinical trial results for the diagnosis of hepatocellular cancer (HCC) for the period 2014–2020. Ann hir gepatol 2021;26:12-24. [DOI: 10.16931/1995-5464.2021112-24] [Reference Citation Analysis]
|
| 536 |
Sabih AH, Laube R, Strasser SI, Lim L, Cigolini M, Liu K. Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. BMJ Support Palliat Care 2021:bmjspcare-2020-002807. [PMID: 33737287 DOI: 10.1136/bmjspcare-2020-002807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 537 |
Mai RY, Zeng J, Meng WD, Lu HZ, Liang R, Lin Y, Wu GB, Li LQ, Ma L, Ye JZ, Bai T. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. BMC Cancer 2021;21:283. [PMID: 33726693 DOI: 10.1186/s12885-021-07969-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 538 |
Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 539 |
Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 540 |
Wang JH, Li WF, Yong CC, Liu YW, Lu SN, Wang CC. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep 2021;11:6041. [PMID: 33723365 DOI: 10.1038/s41598-021-85431-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 541 |
Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol 2021;27:64-72. [PMID: 33723094 DOI: 10.4103/sjg.sjg_636_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 542 |
Yu CL, Weng MS, Chen WC, Chien KT, Chi CW, Chung CH, Huang CW, Wang PC, Chen CC, Tsai AC, Liu SC, Wang SW. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway. Int J Mol Sci 2021;22:2930. [PMID: 33805784 DOI: 10.3390/ijms22062930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 543 |
Czauderna C, Schmidtmann I, Koch S, Pilz L, Heinrich S, Otto G, Mittler J, Lang H, Kloeckner R, Düber C, Sprinzl MF, Worns MA, Galle PR, Marquardt JU, Weinmann A. High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J 2021. [PMID: 33709539 DOI: 10.1177/2050640620972611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 544 |
Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 545 |
Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol 2021;44:1048-59. [PMID: 33709273 DOI: 10.1007/s00270-021-02805-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 546 |
Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 547 |
Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer 2021;21:250. [PMID: 33685409 DOI: 10.1186/s12885-021-07948-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 548 |
Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 549 |
Hong WF, Gu YJ, Wang N, Xia J, Zhou HY, Zhan K, Cheng MX, Cai Y. Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:301-14. [PMID: 34221916 DOI: 10.14218/JCTH.2020.00132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 550 |
Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 551 |
Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 552 |
Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 2021;10:575. [PMID: 33807929 DOI: 10.3390/cells10030575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 553 |
Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, Kanayama K, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Muroyama R, Kato J, Mimura N, Kanda T, Maruyama H, Kato N. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;549:171-8. [PMID: 33676186 DOI: 10.1016/j.bbrc.2021.02.097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 554 |
Bessar AA, Farag A, Abdel Monem SM, Wadea FM, Shaker SE, Ebada MA, Bessar MA. Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. Eur Radiol Exp 2021;5:10. [PMID: 33649930 DOI: 10.1186/s41747-021-00204-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 555 |
Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 556 |
You Y, Long Y, Yan R, Luo L, Zhang M, Li L, Zeng Q, Li K, Zheng R, Xu E. Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study. Front Oncol 2021;11:570312. [PMID: 33732639 DOI: 10.3389/fonc.2021.570312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 557 |
Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol 2021;36:569-80. [PMID: 33709606 DOI: 10.1111/jgh.15415] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 558 |
Ji F, Li J, Liu L, Liang J, Wang X, Liu J, Cai D, Huang R, Zhang J, Wang Q, Nan Y, Li J, Ye Q, Zhang M, Xu Q, Guo F, Zhao C, Liu L, He C, Li Y, Wang W, Kam LY, Tran S, Maeda M, Mizuta A, Li Z, Dang S, Ren W, Zhu Q, Cheung R, Niu J, Xie W, Pan H, Ren H, Wu C, Shang J, Wang F, Nguyen MH. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol 2021;36:767-74. [PMID: 32840326 DOI: 10.1111/jgh.15192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 559 |
Mai RY, Zeng J, Lu HZ, Liang R, Lin Y, Piao XM, Gao X, Wu GB, Wu FX, Ma L, Xiang BD, Li LQ, Ye JZ. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:688-97. [PMID: 32274631 DOI: 10.1007/s11605-020-04575-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 560 |
Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:618-28. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 561 |
Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 562 |
Satala CB, Jung I, Kobori L, Kovacs Z, Fodor D, Szodorai R, Gurzu S. Benefits of the 8th American Joint Committee on Cancer System for Hepatocellular Carcinoma Staging. J Gastrointest Cancer 2021;52:243-8. [PMID: 32173767 DOI: 10.1007/s12029-020-00394-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 563 |
Zhou Y, Zhou X, Ma J, Zhang W, Yan Z, Luo J. Nomogram for Predicting the Prognosis of Patients with Hepatocellular Carcinoma Presenting with Pulmonary Metastasis. Cancer Manag Res 2021;13:2083-94. [PMID: 33688251 DOI: 10.2147/CMAR.S296020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 564 |
Buranupakorn T, Thangsuk P, Patumanond J, Phinyo P. Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:992. [PMID: 33673534 DOI: 10.3390/cancers13050992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 565 |
Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
|
| 566 |
Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 567 |
Yamasaki T, Saeki I, Kotoh-yamauchi Y, Sasaki R, Tanabe N, Oono T, Matsuda T, Hisanaga T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Suehiro Y, Sakaida I. Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Applied Sciences 2021;11:1882. [DOI: 10.3390/app11041882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 568 |
Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2021;12:e00310. [PMID: 33605612 DOI: 10.14309/ctg.0000000000000310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 569 |
Liu J, Li Q, Shi N, Chen Y, Li Y, Zhang M, Huang Y. Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. JGH Open 2021;5:382-9. [PMID: 33732886 DOI: 10.1002/jgh3.12507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 570 |
Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 571 |
Yu C, Song C, Lv J, Zhu M, Yu C, Guo Y, Yang L, Chen Y, Chen Z, Jiang T, Ma H, Jin G, Shen H, Hu Z, Li L; China Kadoorie Biobank Collaborative Group. Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. Int J Cancer 2021;148:2924-34. [PMID: 33521941 DOI: 10.1002/ijc.33487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 572 |
Cassinotto C, Nogue E, Morell M, Panaro F, Molinari N, Guiu B. Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. Eur J Cancer 2021;146:48-55. [PMID: 33582392 DOI: 10.1016/j.ejca.2021.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 573 |
Wang C, Ding ZW, Zheng CG, Wang S, Li ZH, Zhang ZM, Pan J, Wang J, Yang C. COCH predicts survival and adjuvant TACE response in patients with HCC. Oncol Lett 2021;21:275. [PMID: 33732351 DOI: 10.3892/ol.2021.12536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 574 |
Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 575 |
Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value Health Reg Issues 2021;24:82-9. [PMID: 33524900 DOI: 10.1016/j.vhri.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 576 |
Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 577 |
Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 578 |
Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer 2021;10:38-51. [PMID: 33708638 DOI: 10.1159/000512028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 579 |
Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 580 |
Kim NJ, Jacob DA, Ioannou GN, John BV, Rogal S, Rozenberg-Ben-Dror K. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol 2021;116:411-5. [PMID: 33252455 DOI: 10.14309/ajg.0000000000001000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 581 |
Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 582 |
Zhu Z, Xu J, Wu X, Lin S, Li L, Ye W, Huang Z. In Silico Identification of Contradictory Role of ADAMTS5 in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:1533033820986826. [PMID: 33522433 DOI: 10.1177/1533033820986826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 583 |
Geyer T, Rübenthaler J, Marschner C, von Hake M, Fabritius MP, Froelich MF, Huber T, Nörenberg D, Rückel J, Weniger M, Martens C, Sabel L, Clevert DA, Schwarze V. Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. Cancers (Basel) 2021;13:534. [PMID: 33572502 DOI: 10.3390/cancers13030534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 584 |
Shu Z, Gao F, Xia Q, Zhang M. MiR-9-5p promotes cell proliferation and migration of hepatocellular carcinoma by targeting CPEB3. Biomark Med 2021;15:97-108. [PMID: 33496636 DOI: 10.2217/bmm-2020-0322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 585 |
Suceveanu AI, Micu IS, Baltatescu GI, Petcu LC, Dobrin N, Brinzan C, Nitipir C, Mazilu L, Botea F, Herlea V, Voinea F, Suceveanu AP. Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. Exp Ther Med 2021;21:284. [PMID: 33603891 DOI: 10.3892/etm.2021.9715] [Reference Citation Analysis]
|
| 586 |
Zhu G, Song J, Chen W, Yuan D, Wang W, Chen X, Liu H, Su H, Zhu J. Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. Cancer Manag Res 2021;13:659-75. [PMID: 33536782 DOI: 10.2147/CMAR.S275172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 587 |
Geist BK, Xing H, Wang J, Shi X, Zhao H, Hacker M, Sang X, Huo L, Li X. A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging. EJNMMI Phys 2021;8:8. [PMID: 33483880 DOI: 10.1186/s40658-021-00353-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 588 |
Li S, Guo JH, Lu J, Wang C, Wu H, Wang H, Zha J, Fan R. I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis. Cancer Radiother 2021;25:340-9. [PMID: 33455874 DOI: 10.1016/j.canrad.2020.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 589 |
Sukowati CHC, Cabral LKD, Tiribelli C, Pascut D. Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines 2021;9:90. [PMID: 33477833 DOI: 10.3390/biomedicines9010090] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 590 |
Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 591 |
Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One 2021;16:e0244939. [PMID: 33439893 DOI: 10.1371/journal.pone.0244939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 592 |
Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
|
| 593 |
Fang Y, Yuan XD, Liu HH, Xiang L, Chen LM, Fan YC, Gao S, Wang K. 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection. Expert Rev Clin Immunol 2021;17:177-85. [PMID: 33353450 DOI: 10.1080/1744666X.2020.1866987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 594 |
Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 595 |
Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 596 |
Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 597 |
Lim J, Kim HI, Kim E, Kim J, An J, Chang S, Kim SO, Lee HC, Lee YS, Shim JH. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer 2021;21:11. [PMID: 33402105 DOI: 10.1186/s12885-020-07708-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 598 |
Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 599 |
Park SH, Shim YS, Kim B, Kim SY, Kim YS, Huh J, Park JH, Kim KW, Lee SS. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. Eur Radiol 2021;31:4751-63. [PMID: 33389037 DOI: 10.1007/s00330-020-07577-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 600 |
Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 601 |
Al-busafi SA, Alnaamani K. Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_17] [Reference Citation Analysis]
|
| 602 |
Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 56.0] [Reference Citation Analysis]
|
| 603 |
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 264] [Cited by in F6Publishing: 261] [Article Influence: 132.0] [Reference Citation Analysis]
|
| 604 |
Wang Y, Wang M, Li H, Chen K, Zeng H, Bi X, Zhu Z, Jiao Y, Wang Y, Zhu J, Zhao H, Liu X, Dai C, Fan C, Zhao C, Guo D, Zhao H, Zhou J, Wang D, Wu Z, Zhao X, Cui W, Zhang X, Cai J, Chen W, Qu C. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. Chin J Cancer Res 2021;33:352-63. [PMID: 34321832 DOI: 10.21147/j.issn.1000-9604.2021.03.07] [Reference Citation Analysis]
|
| 605 |
Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). J Clin Exp Hepatol 2021;11:674-81. [PMID: 34866846 DOI: 10.1016/j.jceh.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 606 |
Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021;56:261-73. [PMID: 33427937 DOI: 10.1007/s00535-020-01754-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 607 |
Hughes DM, Berhane S, Emily de Groot CA, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kolamunage-Dona R, Amoros R, Bird T, Garcίa-Fiñana M, Johnson P. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021;19:162-170.e4. [PMID: 32389887 DOI: 10.1016/j.cgh.2020.04.084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 608 |
Bhatti ABH. Hepatocellular Carcinoma in Pakistan: An Update. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_25] [Reference Citation Analysis]
|
| 609 |
Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 610 |
Merola A, Brocco S, Quaia E. Percutaneous Ablation of Liver Tumors. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_12] [Reference Citation Analysis]
|
| 611 |
Carr BI. Overview of Clinical HCC and Its Management. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_7] [Reference Citation Analysis]
|
| 612 |
Zhang Y, Zhang J, Chen X, Yang Z. Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma. Int J Med Sci 2021;18:364-71. [PMID: 33390805 DOI: 10.7150/ijms.49790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 613 |
Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S. Application of new ultrasound techniques for focal liver lesions. Jpn J Med Ultrasonics 2021;48:317-340. [DOI: 10.3179/jjmu.jjmu.r.184] [Reference Citation Analysis]
|
| 614 |
Wang J, Feng L, Zhang L. Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101440. [PMID: 32709504 DOI: 10.1016/j.clinre.2020.04.010] [Reference Citation Analysis]
|
| 615 |
Han K. Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_18] [Reference Citation Analysis]
|
| 616 |
Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [PMID: 33029863 DOI: 10.1111/jvh.13411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 617 |
Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 618 |
Rhee H, Cho ES, Nahm JH, Jang M, Chung YE, Baek SE, Lee S, Kim MJ, Park MS, Han DH, Choi JY, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol 2021;74:109-21. [PMID: 32818570 DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 619 |
Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 620 |
Pagano D, Mamone G, Calamia S, Gruttadauria S. Surgical Management of Hepatocellular Carcinoma. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_7-1] [Reference Citation Analysis]
|
| 621 |
Kim H, Choi J, Kim BH, Youn SY, Kim H, Kim DH, Rha SE. LI-RADS version 2018 in Patients with Prior History of Hepatocellular Carcinoma: Are LR4 Observations Enough for the Diagnosis of Recurrent HCC? Investig Magn Reson Imaging 2021;25:172. [DOI: 10.13104/imri.2021.25.3.172] [Reference Citation Analysis]
|
| 622 |
Cappelli A, Peta G, Golfieri R. Transarterial Chemoembolisation and Combined Therapy. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_13] [Reference Citation Analysis]
|
| 623 |
Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 2021;56:181-90. [PMID: 33392749 DOI: 10.1007/s00535-020-01753-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 624 |
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 134] [Cited by in F6Publishing: 146] [Article Influence: 67.0] [Reference Citation Analysis]
|
| 625 |
Sandhu N, Rossi S. Diagnosis and Evaluation of Hepatocellular Carcinoma. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_4-1] [Reference Citation Analysis]
|
| 626 |
Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 627 |
Lim ES, Kim SM, Shin SS, Heo SH, Lee JE, Jeong YY. Diagnostic Performance of Simulated Abbreviated MRI for Early-Stage Hepatocellular Carcinoma Screening: A Comparison to Conventional Dynamic Contrast-Enhanced MRI. J Korean Soc Radiol 2021;82:1218. [DOI: 10.3348/jksr.2020.0172] [Reference Citation Analysis]
|
| 628 |
Kedarisetty CK, Bal S, Parida S, Jain M, Bhadoria AS, Varghese J, Venkataraman J. Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. J Clin Exp Hepatol 2021;11:299-304. [PMID: 33994712 DOI: 10.1016/j.jceh.2020.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 629 |
Martí-bonmatí L, Torregrosa A. Hepatocellular Carcinoma: Diagnostic Guidelines. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_9] [Reference Citation Analysis]
|
| 630 |
Zhang Y, Chen X, Cao Y, Yang Z. C8B in Complement and Coagulation Cascades Signaling Pathway is a predictor for Survival in HBV-Related Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:3503-15. [PMID: 33911900 DOI: 10.2147/CMAR.S302917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 631 |
Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 632 |
Kim H, Kim S, Lee S, Lee M, Kim M. Diagnostic Image Feature and Performance of CT and Gadoxetic Acid Disodium-Enhanced MRI in Distinction of Combined Hepatocellular-Cholangiocarcinoma from Hepatocellular Carcinoma. Investig Magn Reson Imaging 2021;25:313. [DOI: 10.13104/imri.2021.25.4.313] [Reference Citation Analysis]
|
| 633 |
Méndez Romero A, Habraken S, Sprengers D. Basics of Ablative Radiotherapy: The Background Knowledge Necessary to Practicing Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_7] [Reference Citation Analysis]
|
| 634 |
Rim CH, Seong J. Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_11] [Reference Citation Analysis]
|
| 635 |
Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 636 |
Sheng X, Ji Y, Ren GP, Lu CL, Yun JP, Chen LH, Meng B, Qu LJ, Duan GJ, Sun Q, Ye XQ, Li SS, Yang J, Liao B, Wang ZB, Zhou JH, Sun Y, Qiu XS, Wang L, Li ZS, Chen J, Xia CY, He S, Li CY, Xu EW, Geng JS, Pan C, Kuang D, Qin R, Guan HW, Wang ZD, Li LX, Zhang X, Wang H, Zhao Q, Wei B, Zhang WJ, Ling SP, Du X, Cong WM; Liver Cancer Pathology Group of China (LCPGC). A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int 2020;14:1034-47. [PMID: 33369707 DOI: 10.1007/s12072-020-10111-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 637 |
Abouzied MM, Fathala A, AlMuhaideb A, Almanea H, Al-Sugair AS, AlSkaff R, Al-Qahtani MH. Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. Radiol Case Rep 2021;16:550-4. [PMID: 33384755 DOI: 10.1016/j.radcr.2020.12.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 638 |
Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 639 |
Leeming DJ, Nielsen SH, Vongsuvanh R, Uchila P, Nielsen MJ, Reese-Petersen AL, van der Poorten D, Eslam M, Schuppan D, Karsdal MA, George J. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepat Oncol 2020;8:HEP32. [PMID: 34084451 DOI: 10.2217/hep-2020-0030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 640 |
Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 641 |
Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 642 |
Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 643 |
Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules 2020;10:E1673. [PMID: 33333800 DOI: 10.3390/biom10121673] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 644 |
Hao W, Binbin J, Wei Y, Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front Oncol 2020;10:561669. [PMID: 33312946 DOI: 10.3389/fonc.2020.561669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 645 |
Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 646 |
Han B, Ding H, Zhao S, Zhang Y, Wang J, Zhang Y, Gu J. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. Front Oncol 2020;10:562103. [PMID: 33365268 DOI: 10.3389/fonc.2020.562103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 647 |
Lee HA, Park S, Seo YS, Yoon WS, Shin I, Rim CH. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis. J Hepatobiliary Pancreat Sci. [DOI: 10.1002/jhbp.865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 648 |
Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, Brade A, Dinniwell R, Wong RKS, Cho C, Kim TK, Sapisochin G, Dawson LA. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120-126. [PMID: 33285195 DOI: 10.1016/j.radonc.2020.11.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 649 |
Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 650 |
Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 651 |
Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 652 |
Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 653 |
Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 223] [Cited by in F6Publishing: 234] [Article Influence: 74.3] [Reference Citation Analysis]
|
| 654 |
Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, Shi J, Wu MC, Lau WY, Cheng SQ. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9:717-728. [PMID: 33299827 DOI: 10.21037/hbsn.2019.10.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 655 |
Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [PMID: 32064645 DOI: 10.1002/hep.31187] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 656 |
Eslam M, Sarin SK, Wong VW, Fan J, Kawaguchi T, Ahn SH, Zheng M, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao J, Hamid S, Cua IH, Chan W, Payawal D, Tan S, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919. [DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 260] [Cited by in F6Publishing: 199] [Article Influence: 86.7] [Reference Citation Analysis]
|
| 657 |
Jiang Z, Zhang Y, Liu X, Liang J, Qiu G, Zhu X, Chen J, Li L. Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:12341-55. [PMID: 33293827 DOI: 10.2147/OTT.S278912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 658 |
Li J, Yang H, Yeh M, Le MH, Le AK, Yeo YH, Dai C, Barnett S, Zhang JQ, Huang J, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu M, Nguyen MH. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of Infectious Diseases 2021;224:294-302. [DOI: 10.1093/infdis/jiaa739] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 659 |
Chen YY, Wang CC, Liu YW, Li WF, Chen YH. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PeerJ 2020;8:e10382. [PMID: 33240675 DOI: 10.7717/peerj.10382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 660 |
Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 661 |
Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 662 |
Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 663 |
Guarino M, Caporaso N, Morisco F. Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy. Ann Transl Med 2020;8:1282. [PMID: 33209862 DOI: 10.21037/atm-20-6004] [Reference Citation Analysis]
|
| 664 |
Takashima H, Moriguchi M, Hayashi N, Ikeda K, Ogiso K, Yokomizo C, Uejima H, Itoh T, Tomioka H, Mizuno S, Shimizu S, Yasui K, Itoh Y. A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. Case Rep Oncol 2020;13:1337-1342. [DOI: 10.1159/000510043] [Reference Citation Analysis]
|
| 665 |
Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 666 |
Shao YY, Wang SY, Lin SM; Diagnosis Group,., Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 2021;120:1051-60. [PMID: 33199101 DOI: 10.1016/j.jfma.2020.10.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 667 |
Li B, Huang H, Huang R, Zhang W, Zhou G, Wu Z, Lv C, Han X, Jiang L, Li Y, Li B, Zhang Z. SEPT9 Gene Methylation as a Noninvasive Marker for Hepatocellular Carcinoma. Dis Markers 2020;2020:6289063. [PMID: 33178361 DOI: 10.1155/2020/6289063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 668 |
Shiina S, Gani RA, Yokosuka O, Maruyama H, Nagamatsu H, Payawal DA, Dokmeci AK, Lesmana LA, Tanwandee T, Lau G, Sarin SK, Omata M. APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatol Int. 2020;14:920-929. [PMID: 33174159 DOI: 10.1007/s12072-020-10103-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 669 |
Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 670 |
Xu W, Liu F, Shen X, Li R. Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. J Hepatocell Carcinoma 2020;7:233-56. [PMID: 33154956 DOI: 10.2147/JHC.S271498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 671 |
Min JH, Kang TW, Kim YY, Cha DI, Kim YK, Kim SH, Sinn DH, Ha SY, Kim K. Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. Eur Radiol 2021;31:3315-25. [PMID: 33159576 DOI: 10.1007/s00330-020-07438-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 672 |
Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 673 |
Kim DW, Choi SH, Kim SY, Byun JH, Lee SS, Park SH, Kim KW. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 2020;14:1009-22. [DOI: 10.1007/s12072-020-10100-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 674 |
Kwon JW, Tchoe HJ, Lee J, Suh JK, Lee JH, Shin S. The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. Gut Liver 2020;14:108-16. [PMID: 30974929 DOI: 10.5009/gnl18522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 675 |
Kang HJ, Lee JM, Yoon JH, Han JK. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. Korean J Radiol 2021;22:354-65. [PMID: 33236540 DOI: 10.3348/kjr.2020.0973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 676 |
Wu H, Liu TT, Feng YM, Xie XY, Su XN, Qi JN, Zhu Q, Qin CY. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. J Dig Dis 2020;21:650-63. [PMID: 32959529 DOI: 10.1111/1751-2980.12941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 677 |
Jang TY, Wei YJ, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. J Gastroenterol Hepatol 2020;35:1886-92. [PMID: 32247291 DOI: 10.1111/jgh.15061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 678 |
Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 679 |
Ke L, Shen R, Fan W, Hu W, Shen S, Li S, Kuang M, Liang L, Li J, Peng B, Hua Y. The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2020;8:1402. [PMID: 33313147 DOI: 10.21037/atm-20-2420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 680 |
Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:577-90. [PMID: 33012446 DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 681 |
Shiha G, Waked I, Soliman R, Elbasiony M, Gomaa A, Mikhail NNH, Eslam M. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. Liver Int 2020;40:2828-33. [PMID: 32946647 DOI: 10.1111/liv.14666] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 682 |
Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 683 |
Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 684 |
Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 685 |
Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 686 |
Shi K, Liu Y, Wang X, Li Y, Zhang Q, Hu Y, Ran C, Huang Y, Hou J, Wang X. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evid Based Complement Alternat Med 2020;2020:8826091. [PMID: 33178324 DOI: 10.1155/2020/8826091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 687 |
Ricke J, Steffen IG, Bargellini I, Berg T, Bilbao Jaureguizar JI, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Seidensticker M. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2020;2:100173. [PMID: 33103093 DOI: 10.1016/j.jhepr.2020.100173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 688 |
Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, Kim KW, Lee SS. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Korean J Radiol 2020;21:280-9. [PMID: 32090520 DOI: 10.3348/kjr.2019.0447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 689 |
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 2020;371:m3544. [PMID: 33106289 DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 122] [Cited by in F6Publishing: 96] [Article Influence: 40.7] [Reference Citation Analysis]
|
| 690 |
Liu M, Wu R, Liu X, Xu H, Chi X, Wang X, Zhan M, Wang B, Peng F, Gao X, Shi Y, Wen X, Ji Y, Jin Q, Niu J. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. J Hepatocell Carcinoma 2020;7:219-32. [PMID: 33123501 DOI: 10.2147/JHC.S271790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 691 |
Shen T, Lu Y, Zhang Q. High Squalene Epoxidase in Tumors Predicts Worse Survival in Patients With Hepatocellular Carcinoma: Integrated Bioinformatic Analysis on NAFLD and HCC. Cancer Control 2020;27:1073274820914663. [PMID: 32216563 DOI: 10.1177/1073274820914663] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 692 |
Guo J, Liu S, Gao S, Kou F, Zhang X, Liu P, Yang R, Zhu X. γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:419-428.e2. [PMID: 33067120 DOI: 10.1016/j.jvir.2020.07.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 693 |
Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer 2021;148:1051-65. [PMID: 32997794 DOI: 10.1002/ijc.33313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 694 |
Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther 2020;13:10267-73. [PMID: 33116607 DOI: 10.2147/OTT.S261521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 695 |
Hwang SH, Hong SB, Park S, Han K, Park YN, Kim SY, Park MS. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI. Eur Radiol 2021;31:2321-31. [PMID: 33044650 DOI: 10.1007/s00330-020-07329-z] [Reference Citation Analysis]
|
| 696 |
Wu H, Liu T, Qi J, Qin C, Zhu Q. Four Autophagy-Related lncRNAs Predict the Prognosis of HCC through Coexpression and ceRNA Mechanism. Biomed Res Int 2020;2020:3801748. [PMID: 33102579 DOI: 10.1155/2020/3801748] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 697 |
Fan PL, Ding H, Mao F, Chen LL, Dong Y, Wang WP. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. Eur J Radiol 2020;132:109341. [PMID: 33069987 DOI: 10.1016/j.ejrad.2020.109341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 698 |
Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 699 |
Kang H, Lee JM, Yoon JH, Lee K, Kim H, Han JK. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk. Radiology 2020;297:108-16. [DOI: 10.1148/radiol.2020200115] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 700 |
Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 701 |
Mai R, Lu H, Bai T, Liang R, Lin Y, Ma L, Xiang B, Wu G, Li L, Ye J. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery 2020;168:643-52. [DOI: 10.1016/j.surg.2020.06.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 702 |
Kim TK, Jang H. Emerging Evidence of the Utility of Perfluorobutane-enhanced US as a Diagnostic Test for Hepatocellular Carcinoma. Radiology 2020;297:117-119. [DOI: 10.1148/radiol.2020202763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 703 |
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 704 |
Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 705 |
Choi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Cho EJ. Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS One 2020;15:e0239733. [PMID: 32986758 DOI: 10.1371/journal.pone.0239733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 706 |
Lee H, Park S, Seo YS, Yoon WS, Shin I, Rim CH. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis.. [DOI: 10.1101/2020.09.20.20198440] [Reference Citation Analysis]
|
| 707 |
Li H, Sun J, Zhu H, Wu H, Zhang H, Gu Z, Luo K. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1670. [PMID: 32949116 DOI: 10.1002/wnan.1670] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 708 |
Su Y, You Y, Zeng Q, Tan L, Ye H, Liu J, Zheng R, Li K. Transcholecystic Contrast-Enhanced Ultrasound-Guided Percutaneous Transhepatic Biliary Drainage for Central Bile Duct Protection During Thermal Tumor Ablation. J Vasc Interv Radiol 2020;31:1587-91. [PMID: 32951970 DOI: 10.1016/j.jvir.2020.05.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 709 |
Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 710 |
Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 711 |
Cheung TT, Ma KW, She WH, Dai WC, Tsang SHY, Chan ACY, Lo CM. Pure laparoscopic versus open major hepatectomy for hepatocellular carcinoma with liver F4 cirrhosis without routine Pringle maneuver - A propensity analysis in a single center. Surg Oncol 2020;35:315-20. [PMID: 32977103 DOI: 10.1016/j.suronc.2020.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 712 |
Lu X, Li Z, Liu Y, Wang Z, Peng F, Yu Q, Fu X, Ji B. The Long-Term Efficacy of Radiofrequency Ablation Versus Laparoscopic Hepatectomy for Small Hepatocellular Carcinoma in East Asia: A Systematic Review and Meta-Analysis. Iran Red Crescent Med J 2020;22. [DOI: 10.5812/ircmj.102876] [Reference Citation Analysis]
|
| 713 |
Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han KH, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [PMID: 32365240 DOI: 10.1111/jvh.13313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 714 |
Brunsing RL, Fowler KJ, Yokoo T, Cunha GM, Sirlin CB, Marks RM. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res 2020;6:59. [PMID: 33381651 DOI: 10.20517/2394-5079.2020.50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 715 |
Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 716 |
Kurniawan J, Gani RA, Hasan I, Sulaiman AS, Lesmana CRA, Jasirwan COM, Kalista KF, Nababan SHH, Zulkifly S. The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management. J Gastrointest Canc 2020;51:829-835. [DOI: 10.1007/s12029-019-00298-7] [Reference Citation Analysis]
|
| 717 |
Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 718 |
Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System. Advances in Clinical Radiology 2020;2:151-163. [DOI: 10.1016/j.yacr.2020.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 719 |
Liu F, Luo L, Liu Z, Wu S, Zhang W, Li Q, Peng Y, Wei Y, Li B. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma. Mol Carcinog 2020;59:1243-55. [PMID: 32869896 DOI: 10.1002/mc.23252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 720 |
Shi W, Kuang S, Cao S, Hu B, Xie S, Chen S, Chen Y, Gao D, Chen Y, Zhu Y, Zhang H, Liu H, Ye M, Sirlin CB, Wang J. Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol. Abdom Radiol (NY) 2020;45:2688-97. [PMID: 32232524 DOI: 10.1007/s00261-020-02485-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 721 |
Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 722 |
Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 723 |
Agnello F, Albano D, Sparacia G, Micci G, Matranga D, Toia P, La Grutta L, Grassedonio E, Lo Re G, Salvaggio G, Midiri M, Galia M. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging 2020;68:169-74. [PMID: 32836213 DOI: 10.1016/j.clinimag.2020.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 724 |
Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH, Chen CH. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. J Surg Oncol 2020;122:1587-94. [PMID: 32815189 DOI: 10.1002/jso.26183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 725 |
Kim TM, Lee JM, Yoon JH, Joo I, Park SJ, Jeon SK, Schmidt B, Martin S. Prediction of microvascular invasion of hepatocellular carcinoma: value of volumetric iodine quantification using preoperative dual-energy computed tomography. Cancer Imaging 2020;20:60. [PMID: 32811570 DOI: 10.1186/s40644-020-00338-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 726 |
Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 727 |
Chen W, Yang J, Fang H, Li L, Sun J. Relevance Function of Linc-ROR in the Pathogenesis of Cancer. Front Cell Dev Biol 2020;8:696. [PMID: 32850817 DOI: 10.3389/fcell.2020.00696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 728 |
Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 729 |
Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore) 2020;99:e21454. [PMID: 32769872 DOI: 10.1097/MD.0000000000021454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 730 |
Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 731 |
Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol 2020;35:1277-87. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 732 |
Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 733 |
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69:1492-501. [PMID: 31801872 DOI: 10.1136/gutjnl-2019-318934] [Cited by in Crossref: 221] [Cited by in F6Publishing: 249] [Article Influence: 73.7] [Reference Citation Analysis]
|
| 734 |
Min JH, Kim JM, Kim YK, Cha DI, Kang TW, Kim H, Choi GS, Choi SY, Ahn S. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Clin Gastroenterol Hepatol 2020;18:2091-2100.e7. [PMID: 31843599 DOI: 10.1016/j.cgh.2019.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 735 |
Imai K, Yamashita YI, Nakao Y, Matsumoto T, Kinoshita S, Yusa T, Kitano Y, Kaida T, Hayashi H, Baba H. Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function? Ann Surg Oncol 2021;28:854-62. [PMID: 32740735 DOI: 10.1245/s10434-020-08960-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 736 |
Kumar A. Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma? J Hepatol 2020;73:467-8. [PMID: 32409208 DOI: 10.1016/j.jhep.2020.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 737 |
Wang D, Xu Y, Goldstein JB, Ye K, Hu X, Xiao L, Li L, Chang L, Guan Y, Long G, He Q, Yi X, Zhang J, Wang Z, Xia X, Zhou L. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int 2020;40:1997-2007. [PMID: 32279416 DOI: 10.1111/liv.14463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 738 |
Manzini G, Hines IN, Henne-Bruns D, Kremer M. Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines. HPB (Oxford) 2020;22:1206-15. [PMID: 31959487 DOI: 10.1016/j.hpb.2019.12.009] [Reference Citation Analysis]
|
| 739 |
Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2020;9:382-96. [PMID: 32999866 DOI: 10.1159/000507022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 740 |
Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 118] [Cited by in F6Publishing: 132] [Article Influence: 39.3] [Reference Citation Analysis]
|
| 741 |
Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 742 |
Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Moriyama M. Application of artificial intelligence in hepatology: Minireview. Artif Intell Gastroenterol 2020; 1(1): 5-11 [DOI: 10.35712/aig.v1.i1.5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 743 |
Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 744 |
Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 745 |
Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 746 |
Li J, Zhang L, Sun Z, Ge Y, Xiao H, Xie Q, Hu S. Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: Initial experience and findings. J Contemp Brachytherapy 2020;12:233-40. [PMID: 32695194 DOI: 10.5114/jcb.2020.96863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 747 |
Dai J, Zhao J, Du Y, Zhuang L, McNeil EB, Chongsuvivatwong V. Adherence to Hepatocellular Carcinoma Surveillance and Perceived Barriers Among High-Risk Chronic Liver Disease Patients in Yunnan, China. Cancer Manag Res 2020;12:6209-20. [PMID: 32884337 DOI: 10.2147/CMAR.S259195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 748 |
Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 749 |
An C, Lee CH, Byun JH, Lee MH, Jeong WK, Choi SH, Kim DY, Lim YS, Kim YS, Kim JH, Choi MS, Kim MJ. Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. Korean J Radiol 2019;20:1616-26. [PMID: 31854149 DOI: 10.3348/kjr.2019.0363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 750 |
Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci 2020;21:E4906. [PMID: 32664553 DOI: 10.3390/ijms21144906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 751 |
Sumiya T, Mizumoto M, Oshiro Y, Baba K, Murakami M, Shimizu S, Nakamura M, Hiroshima Y, Ishida T, Iizumi T, Saito T, Numajiri H, Nakai K, Okumura T, Sakurai H. Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1840. [PMID: 32650519 DOI: 10.3390/cancers12071840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 752 |
Shi Q, Chen D, Zhou C, Liu J, Huang S, Yang C, Xiong B. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cancer Manag Res 2020;12:5461-8. [PMID: 32753963 DOI: 10.2147/CMAR.S255960] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 753 |
Nouso K, Ohki T, Yamashita T, Takaki H, Liu C, Kang TW, Lee DH, Lee SJ, Kulkarni S, Shree D, Tanaka M. Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. Applied Sciences 2020;10:4607. [DOI: 10.3390/app10134607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 754 |
Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. Eur J Gastroenterol Hepatol 2020;32:882-8. [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 755 |
Zhang Z, Chen J, Jiang H, Wei Y, Zhang X, Cao L, Duan T, Ye Z, Yao S, Pan X, Song B. Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. Ann Transl Med 2020;8:870. [PMID: 32793714 DOI: 10.21037/atm-20-3041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 756 |
Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 757 |
Yamashita YI, Hayashi H, Imai K, Okabe H, Nakagawa S, Kitamura F, Uemura N, Nakao Y, Yusa T, Itoyama R, Yamao T, Umesaki N, Miyata T, Chikamoto A, Shimokawa M, Baba H. Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. World J Surg 2019;43:2894-901. [PMID: 31312946 DOI: 10.1007/s00268-019-05085-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 758 |
Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 759 |
Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 760 |
Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 761 |
Sidorov DV, Lozhkin MV, Petrov LO, Isaeva AG, Gusakova MS. Combined extensive liver resections in patients with locally advanced hepatocellular cancer – clinical cases. Issled prakt med (Print) 2020;7:154-163. [DOI: 10.17709/2409-2231-2020-7-2-14] [Reference Citation Analysis]
|
| 762 |
Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 763 |
Zhang YX, Zhang XH, Yu XL, Han ZY, Yu J, Liu FY, Cheng ZG, Liang P. Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference? Int J Hyperthermia 2020;37:688-95. [PMID: 32558602 DOI: 10.1080/02656736.2020.1778198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 764 |
Chen L, Ying X, Zhang D, Lai L, Wu F, Tu J, Ji J. Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation. Cancer Biother Radiopharm 2020. [PMID: 32551979 DOI: 10.1089/cbr.2020.3647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 765 |
Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 766 |
Liu J, Xu R, Mai SJ, Ma YS, Zhang MY, Cao PS, Weng NQ, Wang RQ, Cao D, Wei W, Guo RP, Zhang YJ, Xu L, Chen MS, Zhang HZ, Huang L, Fu D, Wang HY. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. Theranostics 2020;10:7527-44. [PMID: 32685003 DOI: 10.7150/thno.45989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 767 |
Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 768 |
Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 769 |
Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 770 |
Wang DC, Jang H, Kim TK. Characterization of Indeterminate Liver Lesions on CT and MRI With Contrast-Enhanced Ultrasound: What Is the Evidence? American Journal of Roentgenology 2020;214:1295-304. [DOI: 10.2214/ajr.19.21498] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 771 |
Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 73] [Cited by in F6Publishing: 89] [Article Influence: 24.3] [Reference Citation Analysis]
|
| 772 |
Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 29.7] [Reference Citation Analysis]
|
| 773 |
Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clinical Imaging 2020;62:63-8. [DOI: 10.1016/j.clinimag.2020.02.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 774 |
Putzer D, Schullian P, Eberle G, Bale RJ. Thermal ablation—an option in curative treatment of HCC. memo 2020;13:207-211. [DOI: 10.1007/s12254-020-00600-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 775 |
Zhen SH, Cheng M, Tao YB, Wang YF, Juengpanich S, Jiang ZY, Jiang YK, Yan YY, Lu W, Lue JM, Qian JH, Wu ZY, Sun JH, Lin H, Cai XJ. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. Front Oncol. 2020;10:680. [PMID: 32547939 DOI: 10.3389/fonc.2020.00680] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 776 |
Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 777 |
APASL Covid-19 Task Force. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [PMID: 32447721 DOI: 10.1007/s12072-020-10054-w] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 778 |
Lin WC, Lin YS, Chang CW, Chang CW, Wang TE, Wang HY, Chen MJ. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS One. 2020;15:e0233212. [PMID: 32442193 DOI: 10.1371/journal.pone.0233212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 779 |
Choi MH, Choi JI, Lee YJ. Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). Ultrasonography 2021;40:237-47. [PMID: 32660211 DOI: 10.14366/usg.20052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 780 |
Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
